<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUOXETINE - fluoxetine hydrochloride capsule </strong><br>ScieGen Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use fluoxetine capsules, USP safely and effectively. See full prescribing information for fluoxetine capsules, USP.<br><br><br>FLUOXETINE capsules, USP for oral use<br><br>Initial U.S. Approval: 1987</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul class="Disc">
<li><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants (<a href="#Section_5.1">5.1</a>).</span></li>
<li><span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#Section_5.1">5.1</a>).</span></li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Italics">When using fluoxetine and olanzapine in combination, also refer to Boxed Warning section of the package insert for Symbyax.</span></span><span class="Bold"></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">
                           Warnings and Precautions:
                           <br><br>          Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>  (<a href="#Section_5.17">5.8</a>)                                 07/2014 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul class="Disc">
<li><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants (<a href="#Section_5.1">5.1</a>).</span></li>
<li><span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#Section_5.1">5.1</a>).</span></li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Italics">When using fluoxetine and olanzapine in combination, also refer to Boxed Warning section of the package insert for Symbyax.</span></span><span class="Bold"></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: </p>
<ul class="Disc">
<li>Acute and maintenance treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) (<a href="#Section_1">1</a>)</li>
<li>Acute and maintenance treatment of <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD) (<a href="#Section_1">1</a>)</li>
<li>Acute and maintenance treatment of <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span> (<a href="#Section_1">1</a>)</li>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span>, with or without <span class="product-label-link" type="condition" conceptid="4321835" conceptname="Agoraphobia">agoraphobia</span> (<a href="#Section_1">1</a>)</li>
</ul>
<p class="Highlighta"><span class="Italics">Fluoxetine capsules and olanzapine in combination for treatment of:</span> </p>
<ul class="Disc"><li>Acute <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<a href="#Section_1">1</a>)</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Indication</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Adult</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Pediatric</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">MDD (<a href="#Section_2.1">2.1</a>)
                                    <br>
</td>
<td class="Rrule" valign="top">20 mg/day in am (initial dose)<br>
</td>
<td class="Rrule" valign="top">10 to 20 mg/day (initial dose)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">OCD (<a href="#Section_2.2">2.2</a>)
                                    <br>
</td>
<td class="Rrule" valign="top">20 mg/day in am (initial dose)<br>
</td>
<td class="Rrule" valign="top">10 mg/day (initial dose)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span> (<a href="#Section_2.3">2.3</a>)
                                    <br>
</td>
<td class="Rrule" valign="top">60 mg/day in am<br>
</td>
<td class="Rrule" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Panic Disorder (<a href="#Section_2.4">2.4</a>)
                                    <br>
</td>
<td class="Rrule" valign="top">10 mg/day (initial dose)<br>
</td>
<td class="Rrule" valign="top"><br></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span><br>Associated with Bipolar I <br> Disorder (<a href="#Section_2.5">2.5</a>)
                                    <br>
</td>
<td class="Rrule" valign="top">Oral in combination with<br>            olanzapine: 5 mg of oral<br>            olanzapine and 20 mg of<br>            fluoxetine once daily (initial dose)<br>
</td>
<td class="Rrule" valign="top"><br></td>
</tr>
</tbody></table>
<ul class="Disc"><li>A lower or less frequent dosage should be used in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the elderly, and for patients with concurrent disease or on multiple concomitant medications (<a href="#Section_2.7">2.7</a>) </li></ul>
<p class="Highlighta"><span class="Italics">Fluoxetine capsules and olanzapine in combination:</span> </p>
<ul class="Disc">
<li>Dosage adjustments should be made with the individual components according to efficacy and tolerability (<a href="#Section_2.5">2.5</a>)   </li>
<li>Fluoxetine monotherapy is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<a href="#Section_2.5">2.5</a>)
                           </li>
<li>Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated (<a href="#Section_2.5">2.5</a>)
                           </li>
</ul>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Capsules: 10 mg, 20 mg, and 40 mg (<a href="#Section_3">3</a>)
                           </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine. Do not use fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start fluoxetine in a patient who is being treated with linezolid or intravenous methylene blue (<a href="#Section_4.2">4.1</a>)
                           </li>
<li>Pimozide: Do not use. Risk of QT prolongation and drug interaction (<a href="#Section_4.1">4.2</a>, <a href="#Section_5.10">5.11</a>, <a href="#Section_7.7">7.7</a>, <a href="#Section_7.8">7.8</a>)
                           </li>
<li>Thioridazine: Do not use. Risk of QT interval prolongation and elevated thioridazine plasma levels. Do not use thioridazine within 5 weeks of discontinuing fluoxetine. Do not use thioridazine within 5 weeks of discontinuing fluoxetine (<a href="#Section_4.1">4.2</a>, <a href="#Section_5.10">5.11</a>, <a href="#Section_7.7">7.7</a>, <a href="#Section_7.8">7.8</a>) </li>
<li>When using fluoxetine and olanzapine in combination, also refer to the Contraindications section of the package insert for Symbyax (<a href="#Section_4">4</a>) </li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Suicidal thoughts and Behaviors in Children, Adolescents, and Young Adults: </span>Monitor for clinical worsening and suicidal thinking and behavior (<a href="#Section_5.1">5.1</a>)
                           </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: </span><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported with SSRIs and SNRIs, including fluoxetine<span class="Italics">, </span>both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's Wort). If such symptoms occur, discontinue fluoxetine and initiate supportive treatment. If concomitant use of fluoxetine with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly during treatment initiation and dose increases. (<a href="#Section_5.2">5.2</a>)
                           </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>: </span>Discontinue upon appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or allergic phenomena (<a href="#Section_5.3">5.3</a>)
                           </li>
<li>
<span class="Italics">Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span>: </span>Screen for Bipolar Disorder and monitor for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> (<a href="#Section_5.4">5.4</a>)
                           </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: </span>Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (<a href="#Section_5.5">5.5</a>)
                           </li>
<li>
<span class="Italics">Altered Appetite and Weight: </span>Significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> has occurred (<a href="#Section_5.6">5.6</a>)
                           </li>
<li>
<span class="Italics">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: </span>May increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Use with NSAIDs, aspirin, warfarin, or other drugs that affect coagulation may potentiate the risk of gastrointestinal or other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#Section_5.7">5.7</a>)
                           </li>
<li>Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>: Angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> has occurred in patients with untreated anatomically narrow angles treated with antidepressants. (<a href="#Section_5.17">5.8</a>)
                           </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>: </span>Has been reported with fluoxetine in association with syndrome of inappropriate antidiuretic hormone (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Consider discontinuing if symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> occurs (<a href="#Section_5.8">5.9</a>)
                           </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>: </span>May occur (<a href="#Section_5.9">5.10</a>)
                           </li>
<li>
<span class="Italics">QT Prolongation: </span>QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> have been reported with fluoxetine use. Use with caution in conditions that predispose to <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or increased fluoxetine exposure. Use cautiously in patients with risk factors for QT prolongation (<a href="#Section_4.1">4.2</a>, <a href="#Section_5.10">5.11</a>, <a href="#Section_7.7">7.7</a>, <a href="#Section_7.8">7.8</a>, <a href="#Section_10.1">10.1</a>)</li>
<li>
<span class="Italics">Potential for Cognitive and Motor Impairment: </span>Has potential to impair judgment, thinking, and motor skills. Use caution when operating machinery (<a href="#Section_5.12">5.13</a>)
                           </li>
<li>
<span class="Italics">Long Half-Life: </span>Changes in dose will not be fully reflected in plasma for several weeks (<a href="#Section_5.13">5.14</a>)
                           </li>
<li>
<span class="Italics">Fluoxetine and Olanzapine in Combination: </span>When using Fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax (<a href="#Section_5.16">5.16</a>)
                           </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (≥5% and at least twice that for placebo) associated with:<br><br>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span>, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span>: <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, and <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawn</span> (<a href="#Section_6.1">6.1</a>)
                           <br><br>Fluoxetine and olanzapine in combination – Also refer to the Adverse Reactions section of the package insert for Symbyax (<a href="#Section_6">6</a>)
                           <br><span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact ScieGen Pharmaceuticals Inc at 1-855-724-3436 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span> </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<br><ul class="Disc">
<li>
<span class="Italics">Monoamine Oxidase Inhibitors (MAOIs): </span>
                              (<a href="#Section_2.9">2.9</a>, <a href="#Section_2.10">2.10</a>, <a href="#Section_4.2">4.1</a>, <a href="#Section_5.2">5.2</a>)</li>
<li>
<span class="Italics">Drugs Metabolized by CYP2D6: </span>Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (<a href="#Section_7.7">7.7</a>)
                           </li>
<li>
<span class="Italics">Tricyclic Antidepressants (TCAs): </span>Monitor TCA levels during coadministration with fluoxetine or when fluoxetine has been recently discontinued (<a href="#Section_5.2">5.2</a>, <a href="#Section_7.7">7.7</a>)
                           </li>
<li>
<span class="Italics">CNS Acting Drugs: </span>Caution should be used when taken in combination with other centrally acting drugs (<a href="#Section_7.2">7.2</a>)
                           </li>
<li>
<span class="Italics">Benzodiazepines: </span>Diazepam – increased t½, alprazolam - further psychomotor performance decrement due to increased levels (<a href="#Section_7.7">7.7</a>)
                           </li>
<li>
<span class="Italics">Antipsychotics: </span>Potential for elevation of haloperidol and clozapine levels (<a href="#Section_7.7">7.7</a>)
                           </li>
<li>
<span class="Italics">Anticonvulsants: </span>Potential for elevated phenytoin and carbamazepine levels and clinical <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">anticonvulsant toxicity</span> (<a href="#Section_7.7">7.7</a>)
                           </li>
<li>
<span class="Italics">Serotonergic Drugs: </span>
                              (<a href="#Section_2.9">2.9</a>, <a href="#Section_2.10">2.10</a>, <a href="#Section_4.2">4.1</a>, <a href="#Section_5.2">5.2</a>)
                           </li>
<li>
<span class="Italics">Drugs that Interfere with Hemostasis (e.g. NSAIDs, Aspirin, Warfarin): </span>May potentiate the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#Section_7.4">7.4</a>)
                           </li>
<li>
<span class="Italics">Drugs Tightly Bound to Plasma Proteins: </span>May cause a shift in plasma concentrations (<a href="#Section_7.6">7.6</a>, <a href="#Section_7.7">7.7</a>)
                           </li>
<li>
<span class="Italics">Olanzapine: </span>When used in combination with fluoxetine, also refer to the Drug Interactions section of the package insert for Symbyax (<a href="#Section_7.7">7.7</a>)
                           </li>
<li>
<span class="Italics">Drugs that Prolong the QT Interval: </span>Do not use fluoxetine with thioridazine or pimozide. Use with caution in combination with other drugs that prolong the QT interval (<a href="#Section_4.1">4.2</a>, <a href="#Section_5.10">5.11</a>, <a href="#Section_7.7">7.7</a>, <a href="#Section_7.8">7.8</a>)
                           </li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<br><ul class="Disc">
<li>
<span class="Italics">Pregnancy: </span>Fluoxetine should be used during pregnancy only if the potential benefit justifies the potential risks to the fetus (<a href="#Section_8.1">8.1</a>)
                           </li>
<li>
<span class="Italics">Nursing Mothers: </span>Breast feeding is not recommended (<a href="#Section_8.3">8.3</a>)
                           </li>
<li>
<span class="Italics">Pediatric Use: </span>Safety and effectiveness of fluoxetine in patients &lt;8 years of age with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> and &lt;7 years of age with OCD have not been established. Safety and effectiveness of fluoxetine and olanzapine in combination in patients &lt;10 years of age for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> have not been established. (<a href="#Section_8.4">8.4</a>)
                           </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span>Lower or less frequent dosing may be appropriate in patients with cirrhosis (<a href="#Section_8.6">8.6</a>)
                           </li>
</ul>
<p class="Highlighta"><span class="Italics">Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Fluoxetine capsules and Olanzapine in Combination: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.7 Dosing in Specific Populations</a></h2>
<h2><a href="#section-2.7" class="toc">2.8 Discontinuation of Treatment</a></h2>
<h2><a href="#section-2.8" class="toc">2.9 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</a></h2>
<h2><a href="#section-2.9" class="toc">2.10 Use of Fluoxetine with Other MAOIs such as Linezolid or Methylene Blue</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Other Contraindications</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Screening Patients for Bipolar Disorder and Monitoring for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Altered Appetite and Weight</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 QT Prolongation</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Use in Patients with Concomitant Illness</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Potential for Cognitive and Motor Impairment</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Long Elimination Half-Life</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Discontinuation of Adverse Reactions</a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Fluoxetine and Olanzapine in Combination</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Other Reactions</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors (MAOI)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CNS Acting Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Serotonergic Drugs</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, Warfarin)</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Electroconvulsive Therapy (ECT)</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Potential for Other Drugs to affect Fluoxetine</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Potential for Fluoxetine to affect Other Drugs</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Drugs that Prolong the QT Interval</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Animal Experience</a></h2>
<h2><a href="#section-10.3" class="toc">10.3 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.4" class="toc">12.4 Specific Populations</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span></a></h2>
<h2><a href="#section-14.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span></a></h2>
<h2><a href="#section-14.4" class="toc">14.4 <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 General Information</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-16.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-16.8" class="toc">17.8 QT Prolongation</a></h2>
<h2><a href="#section-16.9" class="toc">17.9 Potential for Cognitive and Motor Impairment</a></h2>
<h2><a href="#section-16.10" class="toc">17.10 Use of Concomitant Medications</a></h2>
<h2><a href="#section-16.11" class="toc">17.11 Discontinuation of Treatment</a></h2>
<h2><a href="#section-16.12" class="toc">17.12 Use in Specific Populations</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-1"></a><p></p>
<h1>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<ul class="Disc">
<li><span class="Bold">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.</span></li>
<li><span class="Bold">In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.</span></li>
<li>
<span class="Bold">Fluoxetine </span><span class="Bold">is not approved for use in children less than 7 years of age <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a> and <a href="#Section_8.4">Use in Specific Populations (8.4)</a>]</span>.</span>
</li>
</ul>
<p class="First"><span class="Bold">When using fluoxetine and olanzapine in combination, also refer to Boxed Warning section of the package insert for Symbyax.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Fluoxetine is indicated for the treatment of:</p>
<br><ul class="Disc">
<li>Acute and maintenance treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>.</li>
<li>Acute and maintenance treatment of obsessions and compulsions in patients with <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD) <span class="Italics">[see <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.</li>
<li>Acute and maintenance treatment of binge-eating and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> behaviors in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span> <span class="Italics">[see <a href="#Section_14.3">Clinical Studies (14.3)</a>]</span>.</li>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span>, with or without <span class="Italics"><span class="product-label-link" type="condition" conceptid="4321835" conceptname="Agoraphobia">agoraphobia</span> [see <a href="#Section_14.4">Clinical Studies (14.4)</a>]</span>.</li>
</ul>
<br><p>Fluoxetine  and Olanzapine in Combination is indicated for the treatment of:</p>
<br><ul class="Disc"><li>Acute treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>.</li></ul>
<p>Fluoxetine monotherapy is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>.<br><span class="Italics"><br>When using Fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax<span class="Sup">®</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<p class="First"><span class="Italics">Initial Treatment<br></span><span class="Italics"><br>Adult </span>— Initiate fluoxetine 20 mg/day orally in the morning. Consider a dose increase after several weeks if insufficient clinical improvement is observed. Administer doses above 20 mg/day once daily in the morning or twice daily (i.e., morning and noon). The maximum fluoxetine dose should not exceed 80 mg/day.<br><br>In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses ranging from 20 to 80 mg/day. Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> in most cases <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>.<br><span class="Italics"><br>Pediatric (children and adolescents) </span>— Initiate Fluoxetine 10 or 20 mg/day. After 1 week at 10 mg/day, increase the dose to 20 mg/day. However, due to higher plasma levels in lower weight children, the starting and target dose in this group may be 10 mg/day. Consider a dose increase to 20 mg/day after several weeks if insufficient clinical improvement is observed. In the short-term (8 to 9 week) controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, patients were administered fluoxetine doses of 10 to 20 mg/day <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>.<br><span class="Italics"><br>All patients </span>— As with other drugs effective in the treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, the full effect may be delayed until 4 weeks of treatment or longer.<br><br>Periodically reassess to determine the need for maintenance treatment.<br><span class="Italics"><br>Switching Patients to a Tricyclic Antidepressant (TCA) </span>— Dosage of a TCA may need to be reduced, and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a> and <a href="#Section_7.7">Drug Interactions (7.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span></h2>
<p class="First"><span class="Italics">Initial Treatment<br></span><span class="Italics"><br>Adult</span> — Initiate fluoxetine 20 mg/day, orally in the morning. Consider a dose increase after several weeks if insufficient clinical improvement is observed. The full therapeutic effect may be delayed until 5 weeks of treatment or longer. Administer doses above 20 mg/day once daily in the morning or twice daily (i.e., morning and noon). A dose range of 20 to 60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The maximum fluoxetine dose should not exceed 80 mg/day.<br><br>In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fixed daily doses of 20, 40, or 60 mg of fluoxetine or placebo<span class="Italics"> [see <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>. In one of these studies, no dose-response relationship for effectiveness was demonstrated.<br><span class="Italics"><br>Pediatric (children and adolescents)</span> — In adolescents and higher weight children, initiate treatment with a dose of 10 mg/day. After 2 weeks, increase the dose to 20 mg/day. Consider additional dose increases after several more weeks if insufficient clinical improvement is observed. A dose range of 20 to 60 mg/day is recommended.<br><br>In lower weight children, initiate treatment with a dose of 10 mg/day. Consider additional dose increases after several more weeks if insufficient clinical improvement is observed. A dose range of 20 to 30 mg/day is recommended. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg.<br><br>In the controlled clinical trial of fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fluoxetine doses in the range of 10 to 60 mg/day <span class="Italics">[see <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.<br><br>Periodically reassess to determine the need for treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span></h2>
<p class="First"><span class="Italics">Initial Treatment</span> — Administer fluoxetine 60 mg/day in the morning. For some patients it may be advisable to titrate up to this target dose over several days. Fluoxetine doses above 60 mg/day have not been systematically studied in patients with <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>. In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span>, patients were administered fixed daily fluoxetine doses of 20 or 60 mg, or placebo <span class="Italics">[see <a href="#Section_14.3">Clinical Studies (14.3)</a>]</span>. Only the 60 mg dose was statistically significantly superior to placebo in reducing the frequency of binge-eating and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.<br><br>Periodically reassess to determine the need for maintenance treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></h2>
<p class="First"><span class="Italics">Initial Treatment</span> — Initiate treatment with fluoxetine 10 mg/day. After one week, increase the dose to 20 mg/day. Consider a dose increase after several weeks if no clinical improvement is observed. Fluoxetine doses above 60 mg/day have not been systematically evaluated in patients with <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span>. In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span>, patients were administered fluoxetine doses in the range of 10 to 60 mg/day <span class="Italics">[see <a href="#Section_14.4">Clinical Studies (14.4)</a>]</span>. The most frequently administered dose in the 2 flexible-dose clinical trials was 20 mg/day.<br><br>Periodically reassess to determine the need for continued treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Fluoxetine capsules and Olanzapine in Combination: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span></h2>
<p class="First"><span class="Italics">When using fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax.<br></span></p>
<br><p><span class="Italics">Adult —</span> Administer fluoxetine in combination with oral olanzapine once daily in the evening, without regard to meals, generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies. Periodically re-examine the need for continued pharmacotherapy.<br><span class="Italics"><br>Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<br><p>Safety and efficacy of fluoxetine in combination with olanzapine was determined in clinical trials supporting approval of Symbyax (fixed-dose combination of olanzapine and fluoxetine). Symbyax is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per day and 12 mg/50 mg (olanzapine/fluoxetine) per day. The following table demonstrates the appropriate individual component doses of fluoxetine and olanzapine versus Symbyax. Adjust dosage, if indicated, with the individual components according to efficacy and tolerability.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="592">
<caption><span>Table 1:   Approximate Dose Correspondence Between Symbyax<span class="Sup">1</span> and the Combination of Fluoxetine and Olanzapine 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<span class="Bold">   For Symbyax            (mg/day)</span><br>
</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold">Use in Combination</span><br>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">
<span class="Bold">Olanzapine<br>            (mg/day)</span><br>
</th>
<th class="Lrule Rrule Toprule" align="center">
<span class="Bold">Fluoxetine <br>            (mg/day)</span><br>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">1</span>Symbyax (olanzapine/fluoxetine HCL) is a fixed-dose combination of fluoxetine and olanzapine.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">   3 mg olanzapine/25 mg fluoxetine<br>
</td>
<td class="Rrule" align="center" valign="top">2.5<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   6 mg olanzapine/25 mg fluoxetine<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   12 mg olanzapine/25 mg fluoxetine<br>
</td>
<td class="Rrule" align="center" valign="top">10+2.5<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">   6 mg olanzapine/50 mg fluoxetine<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">40+10<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">   12 mg olanzapine/50 mg fluoxetine<br>
</td>
<td class="Rrule" align="center" valign="top">10+2.5<br>
</td>
<td class="Rrule" align="center" valign="top">40+10<br>
</td>
</tr>
</tbody>
</table>
<p>Fluoxetine capsules monotherapy is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.7"></a><a name="section-2.6"></a><p></p>
<h2>2.7 Dosing in Specific Populations</h2>
<p class="First"><span class="Italics">
                              Treatment of Pregnant Women 
                           </span>— When treating pregnant women with fluoxetine, the physician should carefully consider the potential risks and potential benefits of treatment. Neonates exposed to SSRIs or SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding <span class="Italics">[see <a href="#Section_8.1">Use in Specific Populations (8.1)</a>].<br></span><span class="Italics"><br>
                              Geriatric 
                           </span>— Consider a lower or less frequent dosage for the elderly <span class="Italics">[see <a href="#Section_8.5">Use in Specific Populations (8.5)</a>].<br></span><span class="Italics"><br>
                              <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> 
                           </span>— As with many other medications, use a lower or less frequent dosage in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#Section_12.4">Clinical Pharmacology (12.4)</a> and <a href="#Section_8.6">Use in Specific Populations (8.6)</a>].<br></span><span class="Italics"><br>
                              Concomitant Illness 
                           </span>— Patients with concurrent disease or on multiple concomitant medications may require dosage adjustments <span class="Italics">[see Clinical <a href="#Section_12.4">Pharmacology (12.4)</a> and <a href="#Section_5.11">Warnings and Precautions (5.12)</a>].<br></span><span class="Italics"><br>Fluoxetine capsules and Olanzapine in Combination </span>— Use a starting dose of oral olanzapine 2.5 to 5 mg with fluoxetine 20 mg for patients with a predisposition to hypotensive reactions, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or patients who exhibit a combination of factors that may slow the metabolism of olanzapine or fluoxetine in combination (female gender, geriatric age, non-smoking status), or those patients who may be pharmacodynamically sensitive to olanzapine. Titrate slowly and adjust dosage as needed in patients who exhibit a combination of factors that may slow metabolism. Fluoxetine and olanzapine in combination have not been systematically studied in patients over 65 years of age or in patients less than 10 years of age <span class="Italics">[see <a href="#Section_5.16">Warnings and Precautions (5.16)</a> and <a href="#Section_7.7">Drug Interactions (7.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.8"></a><a name="section-2.7"></a><p></p>
<h2>2.8 Discontinuation of Treatment</h2>
<br><p class="First">Symptoms associated with discontinuation of fluoxetine, SNRIs, and SSRIs, have been reported <span class="Italics">[see <a href="#Section_5.14">Warnings and Precautions (5.15)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.9"></a><a name="section-2.8"></a><p></p>
<h2>2.9 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</h2>
<br><p class="First">At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with fluoxetine. Conversely, at least 5 weeks should be allowed after stopping fluoxetine before starting an MAOI intended to treat psychiatric disorders <span class="Italics">[see <a href="#Section_4.2">Contraindications (4.1)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.10"></a><a name="section-2.9"></a><p></p>
<h2>2.10 Use of Fluoxetine with Other MAOIs such as Linezolid or Methylene Blue</h2>
<p class="First">Do not start fluoxetine in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered <span class="Italics">[see <a href="#Section_4.2">Contraindications (4.1)</a>]. <br><br></span>In some cases, a patient already receiving fluoxetine therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> in a particular patient, fluoxetine should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> for five weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with fluoxetine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].<br><br></span>The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with fluoxetine is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with such use <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">• Fluoxetine capsules, USP 10 mg** are white to off white powder filled in size “4? hard gelatin capsules with opaque light blue colored cap and opaque light orange colored body imprinted “SG? on cap and “113? on body with black ink.<br><br>• Fluoxetine capsules, USP 20 mg** are white to off white powder filled in size “2? hard gelatin capsules with opaque light blue colored cap and opaque light green colored body imprinted “SG? on cap and “114? on body with black ink.<br><br>• Fluoxetine capsules, USP 40 mg** are white to off white powder filled in size “0? hard gelatin capsules with opaque light blue colored cap and opaque white colored body imprinted “SG? on cap and “115? on body with black ink.<br><br>**Fluoxetine base equivalent.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<br><p class="First"><span class="Italics">When using </span><span class="Italics">fluoxetine capsules and olanzapine in combination, also refer to the Contraindications section of the package insert for Symbyax.<br></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.2"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class="First">The use of MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine is contraindicated because of an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. The use of fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated <span class="Italics">[see <a href="#Section_2.9">Dosage and Administration (2.9)</a> and <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]. <br><br></span>Starting fluoxetine in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see <a href="#Section_2.10">Dosage and Administration (2.10)</a> and <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span><span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.1"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Other Contraindications</h2>
<p class="First"><br>The use of fluoxetine is contraindicated with the following: </p>
<br><ul class="Disc">
<li>Pimozide <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.11)</a> and <a href="#Section_7.7">Drug Interactions (7.7</a>, <a href="#Section_7.8">7.8)</a>]</span>
</li>
<li>Thioridazine <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.11)</a> and <a href="#Section_7.7">Drug Interactions (7.7</a>, <a href="#Section_7.8">7.8)</a>]</span>
</li>
</ul>
<p>Pimozide and thioridazine prolong the QT interval. Fluoxetine can increase the levels of pimozide and thioridazine through inhibition of CYP2D6. Fluoxetine can also prolong the QT interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"><span class="Italics">When using </span><span class="Italics">fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults</h2>
<br><p class="First">Patients with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.<br><br>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug versus placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 2.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="70%">
<caption><span>Table 2: Suicidality per 1000 Patients Treated 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Age Range </th>
<th class="Lrule Rrule Toprule" align="center">Drug-Placebo Difference in Number of Cases of Suicidality per <br>1000 Patients Treated</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top">Increases Compared to Placebo<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&lt;18<br>
</td>
<td class="Rrule" align="center" valign="top">14 additional cases<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">18-24<br>
</td>
<td class="Rrule" align="center" valign="top">5 additional cases<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top">Decreases Compared to Placebo<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">25-64<br>
</td>
<td class="Rrule" align="center" valign="top">1 fewer case<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">≥65<br>
</td>
<td class="Rrule" align="center" valign="top">6 fewer cases<br>
</td>
</tr>
</tbody>
</table>
<br><p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<br><p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.</p>
<p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms <span class="Italics">[see <a href="#Section_5.14">Warnings and Precautions (5.15)</a>]</span>.</p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. </span>Prescriptions for fluoxetine should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<br><p>It should be noted that fluoxetine is approved in the pediatric population for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> and <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span>.</p>
<br><p><span class="Italics">Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<br><p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with SNRIs and SSRIs, including fluoxetine, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).<br><br><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.<br><br>The concomitant use of fluoxetine with MAOIs intended to treat psychiatric disorders is contraindicated. Fluoxetine should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking fluoxetine. Fluoxetine should be discontinued before initiating treatment with the MAOI <span class="Italics">[see <a href="#Section_4.2">Contraindications (4.1)</a> and <a href="#Section_2.9">Dosage and Administration (2.9,</a><a href="#Section_2.10">2.10)</a>].<br><br></span>If concomitant use of fluoxetine with other serotonergic drugs, i.e., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly during treatment initiation and dose increases.<br><br>Treatment with fluoxetine and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<br><p class="First">In US fluoxetine clinical trials, 7% of 10,782 patients developed various types of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> and/or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. Among the cases of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> reported in premarketing clinical trials, almost a third were withdrawn from treatment because of the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or systemic signs or symptoms associated with the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Clinical findings reported in association with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, and mild transaminase elevation. Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely.<br><br>In premarketing clinical trials, 2 patients are known to have developed a serious cutaneous systemic illness. In neither patient was there an unequivocal diagnosis, but one was considered to have a <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, and the other, a severe desquamating syndrome that was considered variously to be a <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> or <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Other patients have had systemic syndromes suggestive of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>.<br><br>Since the introduction of fluoxetine, systemic reactions, possibly related to <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and including lupus-like syndrome, have developed in patients with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Although these reactions are rare, they may be serious, involving the lung, kidney, or liver. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has been reported to occur in association with these systemic reactions.<br><br><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> alone and in combination, have been reported.<br><br>Pulmonary reactions, including inflammatory processes of varying histopathology and/or <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, have been reported rarely. These reactions have occurred with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> as the only preceding symptom.<br><br>Whether these systemic reactions and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> have a common underlying cause or are due to different etiologies or pathogenic processes is not known. Furthermore, a specific underlying immunologic basis for these reactions has not been identified. Upon the appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or of other possibly allergic phenomena for which an alternative etiology cannot be identified, fluoxetine should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Screening Patients for Bipolar Disorder and Monitoring for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></h2>
<br><p class="First">A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of Bipolar Disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for Bipolar Disorder. Whether any of the symptoms described for clinical worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for Bipolar Disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, Bipolar Disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that fluoxetine and olanzapine in combination is approved for the acute treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> <span class="Italics">[see Warnings and Precautions section of the package insert for Symbyax]</span>. Fluoxetine monotherapy is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>.<br><br>In US placebo-controlled clinical trials for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> was reported in 0.1% of patients treated with fluoxetine and 0.1% of patients treated with placebo. Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> has also been reported in a small proportion of patients with Major <span class="product-label-link" type="condition" conceptid="444100" conceptname="Mood disorder">Affective Disorder</span> treated with other marketed drugs effective in the treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a>]</span>.<br><br>In US placebo-controlled clinical trials for OCD, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> was reported in 0.8% of patients treated with fluoxetine and no patients treated with placebo. No patients reported <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> in US placebo-controlled clinical trials for <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>. In US fluoxetine clinical trials, 0.7% of 10,782 patients reported <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<br><p class="First">In US placebo-controlled clinical trials for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (or reactions described as possibly having been <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) were reported in 0.1% of patients treated with fluoxetine and 0.2% of patients treated with placebo. No patients reported <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in US placebo-controlled clinical trials for either OCD or <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>. In US fluoxetine clinical trials, 0.2% of 10,782 patients reported <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The percentage appears to be similar to that associated with other marketed drugs effective in the treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>. Fluoxetine should be introduced with care in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Altered Appetite and Weight</h2>
<br><p class="First">Significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, especially in <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">underweight</span> depressed or bulimic patients, may be an undesirable result of treatment with fluoxetine.<br><br>In US placebo-controlled clinical trials for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, 11% of patients treated with fluoxetine and 2% of patients treated with placebo reported <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>). <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span> was reported in 1.4% of patients treated with fluoxetine and in 0.5% of patients treated with placebo. However, only rarely have patients discontinued treatment with fluoxetine because of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> or <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a>]</span>.<br><br>In US placebo-controlled clinical trials for OCD, 17% of patients treated with fluoxetine and 10% of patients treated with placebo reported <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>). One patient discontinued treatment with fluoxetine because of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a></span><span class="Italics">]</span>.<br><br>In US placebo-controlled clinical trials for <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span>, 8% of patients treated with fluoxetine 60 mg and 4% of patients treated with placebo reported <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>). Patients treated with fluoxetine 60 mg on average lost 0.45 kg compared with a gain of 0.16 kg by patients treated with placebo in the 16-week double-blind trial. Weight change should be monitored during therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<br><p class="First">SNRIs and SSRIs, including fluoxetine, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anti-coagulants may add to this risk. Case reports and epidemiological studies (case control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> reactions related to SNRIs and SSRIs use have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>.<br><br>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of fluoxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation <span class="Italics">[see <a href="#Section_7.4">Drug Interactions (7.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.17"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First"><span class="Italics">Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span> — The pupillary dilation that occurs following use of many antidepressant drugs including fluoxetine may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<br><p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> has been reported during treatment with SNRIs and SSRIs, including fluoxetine. In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Cases with serum sodium lower than 110 mmol/L have been reported and appeared to be reversible when fluoxetine was discontinued. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SNRIs and SSRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk <span class="Italics">[see <a href="#Section_8.5">Use in Specific Populations (8.5)</a>]</span>. Discontinuation of fluoxetine should be considered in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate medical intervention should be instituted.<br><br>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. More severe and/or acute cases have been associated with <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></h2>
<br><p class="First">In US placebo-controlled clinical trials for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, 12% to 16% of patients treated with fluoxetine and 7% to 9% of patients treated with placebo reported <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, or <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.<br><br>In US placebo-controlled clinical trials for OCD, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> was reported in 28% of patients treated with fluoxetine and in 22% of patients treated with placebo. <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> was reported in 14% of patients treated with fluoxetine and in 7% of patients treated with placebo.<br><br>In US placebo-controlled clinical trials for <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> was reported in 33% of patients treated with fluoxetine 60 mg, and 13% of patients treated with placebo. <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> were reported, respectively, in 15% and 11% of patients treated with fluoxetine 60 mg and in 9% and 5% of patients treated with placebo.<br><br>Among the most common adverse reactions associated with discontinuation (incidence at least twice that for placebo and at least 1% for fluoxetine in clinical trials collecting only a primary reaction associated with discontinuation) in US placebo-controlled fluoxetine clinical trials were <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (2% in OCD), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (1% in combined indications and 2% in <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>), and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> (1% in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>) <span class="Italics">[see Table 5]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-5.11"></a><p></p>
<h2>5.11 QT Prolongation</h2>
<p class="First">Post-marketing cases of QT interval prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> have been reported in patients treated with fluoxetine. Fluoxetine should be used with caution in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>; a previous history of QT prolongation; a family history of <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> or <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span>; and other conditions that predispose to QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>. Such conditions include concomitant use of drugs that prolong the QT interval; <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>; recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, and other significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>; and conditions that predispose to increased fluoxetine exposure (<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, use of CYP2D6 inhibitors, CYP2D6 poor metabolizer status, or use of other highly protein-bound drugs). Fluoxetine is primarily metabolized by CYP2D6 <span class="Italics">[see <a href="#Section_4.1">Contraindications (4.2)</a>, <a href="#Section_7.7">Drug Interactions (7.7,</a><a href="#Section_7.8">7.8)</a>, <a href="#Section_10.1"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> (10.1)</a>, and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>].<br></span><br>Pimozide and thioridazine are contraindicated for use with fluoxetine. Avoid the concomitant use of drugs known to prolong the QT interval. These include specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol,); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) <span class="Italics">[see <a href="#Section_7.7">Drug Interactions (7.7,</a><a href="#Section_7.8">7.8)</a> and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>].<br></span><br>Consider ECG assessment and periodic ECG monitoring if initiating treatment with fluoxetine in patients with risk factors for QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>. Consider discontinuing fluoxetine and obtaining a cardiac evaluation if patients develop signs or symptoms consistent with <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Use in Patients with Concomitant Illness</h2>
<br><p class="First">Clinical experience with fluoxetine in patients with concomitant systemic illness is limited. Caution is advisable in using fluoxetine in patients with diseases or conditions that could affect metabolism or hemodynamic responses.<span class="Italics"><br><br>Cardiovascular </span>— Fluoxetine has not been evaluated or used to any appreciable extent in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were systematically excluded from clinical studies during the product’s premarket testing. However, the electrocardiograms of 312 patients who received fluoxetine in double-blind trials were retrospectively evaluated; no conduction abnormalities that resulted in <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> were observed. The mean heart rate was reduced by approximately 3 beats/min. <span class="Italics"><br><br>Glycemic Control </span>— In patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, fluoxetine may alter glycemic control. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> has occurred during therapy with fluoxetine, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has developed following discontinuation of the drug. As is true with many other types of medication when taken concurrently by patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with fluoxetine is instituted or discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.12"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Potential for Cognitive and Motor Impairment</h2>
<br><p class="First">As with any CNS-active drug, fluoxetine has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the drug treatment does not affect them adversely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.13"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Long Elimination Half-Life</h2>
<br><p class="First">Because of the long elimination half-lives of the parent drug and its major active metabolite, changes in dose will not be fully reflected in plasma for several weeks, affecting both strategies for titration to final dose and withdrawal from treatment. This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of fluoxetine <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.14"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Discontinuation of Adverse Reactions</h2>
<br><p class="First">During marketing of fluoxetine, SNRIs, and SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>. While these reactions are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with fluoxetine. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. Plasma fluoxetine and norfluoxetine concentration decrease gradually at the conclusion of therapy which may minimize the risk of discontinuation symptoms with this drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.16"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Fluoxetine and Olanzapine in Combination</h2>
<br><p class="First">When using fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<ul class="Disc">
<li>Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Screening Patients for Bipolar Disorder and Monitoring for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Altered Appetite and Weight<span class="Italics"> [see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see <a href="#Section_5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li>Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> <span class="Italics">[see <a href="#Section_5.17">Warnings and Precautions (5.8)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> <span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.9)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> <span class="Italics">[see <a href="#Section_5.9">Warnings and Precautions (5.10)</a>]</span>
</li>
<li>QT Prolongation <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.11)</a>]</span>
</li>
<li>Potential for Cognitive and Motor Impairment <span class="Italics">[see <a href="#Section_5.12">Warnings and Precautions (5.13)</a>]</span>
</li>
<li>Discontinuation Adverse Reactions <span class="Italics">[see <a href="#Section_5.14">Warnings and Precautions (5.15)</a>]</span>
</li>
</ul>
<p><span><a name="OLE_LINK1"></a><span class="Italics">When using </span></span><span class="Italics">fluoxetine and olanzapine in combination, also refer to the Adverse Reactions section of the package insert for Symbyax.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<br><p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.<br><br>Multiple doses of fluoxetine have been administered to 10,782 patients with various diagnoses in US clinical trials. In addition, there have been 425 patients administered fluoxetine in panic clinical trials. The stated frequencies represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.<br><span class="Italics"><br>Incidence in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> placebo-controlled clinical trials (excluding data from extensions of trials) </span>— Table 3 enumerates the most common treatment-emergent adverse reactions associated with the use of fluoxetine (incidence of at least 5% for fluoxetine and at least twice that for placebo within at least 1 of the indications) for the treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, and <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span> in US controlled clinical trials and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> in US plus non-US controlled trials. Table 5 enumerates treatment-emergent adverse reactions that occurred in 2% or more patients treated with fluoxetine and with incidence greater than placebo who participated in US Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, and <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span> controlled clinical trials and US plus non-US <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> controlled clinical trials. Table 4 provides combined data for the pool of studies that are provided separately by indication in Table 3. </p>
<br><table frame="void" width="100%">
<caption><span> Table 3: Most Common Treatment-Emergent Adverse Reactions: Incidence in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> Placebo-Controlled Clinical Trials<span class="Sup">1,2</span></span></caption>
<thead>
<tr class="First"><td class="Lrule Rrule Toprule" align="center" colspan="9" valign="top"><span class="Bold">Percentage of Patients Reporting Event </span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">OCD </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Panic Disorder  </span></td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Lrule Rrule Toprule" align="left" colspan="9" valign="top">
<span class="Sup">1</span> Incidence less than 1%.   </td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="9" valign="top">
<span class="Sup">2</span>Includes US data for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials, plus non-US data for <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials. </td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="9" valign="top">
<span class="Sup">3</span>Denominator used was for males only (N=690 fluoxetine Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>; N=410 placebo Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>; N=116 fluoxetine OCD; N=43 placebo OCD; N=14 fluoxetine <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>; N=1 placebo <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>; N=162 fluoxetine panic; N=121 placebo panic). </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Body System/Adverse Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Fluoxetine</span> (N=1728)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo </span> (N=975)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Fluoxetine </span>(N=266)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo </span>(N=89)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Fluoxetine </span> (N=450)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo </span>(N=267)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Fluoxetine </span>(N=425)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo </span> (N=342)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Body as a Whole</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Cardiovascular System</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Digestive System </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">26</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">17</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Nervous System </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">28</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">22</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">33</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">15</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">15</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">17</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Respiratory System </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawn</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Skin and Appendages </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Urogenital System </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span><span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">    <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Abnormal ejaculation</span><span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">--</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1</td>
</tr>
</tbody>
</table>
<br><table border="0" cellpadding="0" cellspacing="0" width="50%">
<caption><span>Table 4: Treatment-Emergent Adverse Reactions: Incidence in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> Placebo-Controlled Clinical Trials<span class="Sup">1, 2</span></span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Percentage of Patients Reporting Event</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD,<br><span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> Combined</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">1</span> Incidence less than 1%.<br><span class="Sup">2</span> Includes US data for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials, plus non-US data for <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Body System/Adverse Reaction</span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Fluoxetine <br>(N=2869)</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Placebo <br>(N=1673)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Body as a Whole</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Rrule" align="center" valign="top">21<br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span><br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Cardiovascular System</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Digestive System</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" valign="top">22<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span><br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span><br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Metabolic and Nutritional Disorders</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Nervous System</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span><br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span><br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span><br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking abnormal</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Respiratory System</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawn</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Skin and Appendages</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span><br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">   Special Senses</span><br>
</td>
<td class="Rrule" align="center" valign="top"><br></td>
<td class="Rrule" align="center" valign="top"><br></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">      <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Associated with discontinuation in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> placebo-controlled clinical trials (excluding data from extensions of trials)</span> — Table 5 lists the adverse reactions associated with discontinuation of fluoxetine treatment (incidence at least twice that for placebo and at least 1% for fluoxetine in clinical trials collecting only a primary reaction associated with discontinuation) in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials, plus non-US <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials. </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="50%">
<caption><span>Table 5: Most Common Adverse Reactions Associated with Discontinuation in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> Placebo-Controlled Clinical Trials<span class="Sup">1</span></span></caption>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">1</span> Includes US Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials, plus non-US <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> clinical trials.<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span>, and <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> Combined</span><br>(N=1533)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></span><br>(N=392)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">OCD</span><br>(N=266)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia</span></span><br>(N=450)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></span><br>(N=425)<span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> (1%)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> (2%)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> (2%)<span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> (2%)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> (1%)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> (1%)<span class="Bold"></span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (1%)<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">--<span class="Bold"></span><br>
</td>
</tr>
</tbody>
</table>
<br><p><span class="Italics">Other adverse reactions in pediatric patients (children and adolescents) </span>— Treatment-emergent adverse reactions were collected in 322 pediatric patients (180 fluoxetine-treated, 142 placebo-treated). The overall profile of adverse reactions was generally similar to that seen in adult studies, as shown in Tables 4 and 5. However, the following adverse reactions (excluding those which appear in the body or footnotes of Tables 4 and 5 and those for which the COSTART terms were uninformative or misleading) were reported at an incidence of at least 2% for fluoxetine and greater than placebo: <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, and <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>.<br><br>The most common adverse reaction (incidence at least 1% for fluoxetine and greater than placebo) associated with discontinuation in 3 pediatric placebo-controlled trials (N=418 randomized; 228 fluoxetine-treated; 190 placebo-treated) was <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> (1.8% for fluoxetine-treated, 0% for placebo-treated). In these clinical trials, only a primary reaction associated with discontinuation was collected.<span class="Italics"><br><br>Male and female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> with SSRIs </span>— Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance, cited in product labeling, are likely to underestimate their actual incidence. In patients enrolled in US Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>, OCD, and <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span> placebo-controlled clinical trials, decreased libido was the only sexual side effect reported by at least 2% of patients taking fluoxetine (4% fluoxetine, &lt;1% placebo). There have been spontaneous reports in women taking fluoxetine of orgasmic dysfunction, including <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>. <br><br>There are no adequate and well-controlled studies examining <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> with fluoxetine treatment.<br><br>Symptoms of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> occasionally persist after discontinuation of fluoxetine treatment.<br><br><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> has been reported with all SSRIs.<br><br>While it is difficult to know the precise risk of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Other Reactions</h2>
<br><p class="First">Following is a list of treatment-emergent adverse reactions reported by patients treated with fluoxetine in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo.<br><br>Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients.<span class="Bold"><br><br>Body as a Whole </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>; <span class="Italics">Rare: </span>acute abdominal syndrome, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>.<span class="Bold"><br><br>Cardiovascular System </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span><span class="Sup">1</span>.<br><br><span class="Bold">Digestive System </span>— <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcer</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="4231580" conceptname="Acute gastric ulcer with hemorrhage">stomach ulcer hemorrhage</span>.<br><br><span class="Bold">Hemic and Lymphatic System </span>— <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.<br><br><span class="Bold">Nervous System </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="4099943" conceptname="Bruxism">bruxism</span><span class="Sup">1</span>, buccoglossal syndrome, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">libido increased</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>.<br><br><span class="Bold">Respiratory System </span>— <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">larynx edema</span>.<br><br><span class="Bold">Skin and Appendages </span>— <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpuric rash</span>.<br><br><span class="Bold">Special Senses </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.<br><br><span class="Bold">Urogenital System </span><span class="Italics"><span class="Bold"></span>— Frequent: </span>micturition disorder;<span class="Italics"> Infrequent: </span><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, gynecological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Sup">2</span>.<br><br><span class="Sup">1</span>MedDRA dictionary term from integrated database of placebo controlled trials of 15870 patients, of which 9673 patients received fluoxetine.<br><span class="Sup">2</span>Group term that includes individual MedDRA terms: cervix <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">hemorrhage uterine</span>, <span class="product-label-link" type="condition" conceptid="4078936" conceptname="Dysfunctional uterine bleeding">dysfunctional uterine bleeding</span>, genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4151132" conceptname="Menometrorrhagia">menometrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, polymenorrhea, <span class="product-label-link" type="condition" conceptid="195321" conceptname="Postmenopausal bleeding">postmenopausal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>. Adjusted for gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<br><p class="First">The following adverse reactions have been identified during post approval use of fluoxetine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure.<br><br>Voluntary reports of adverse reactions temporally associated with fluoxetine that have been received since market introduction and that may have no causal relationship with the drug include the following: <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> (including, for example, a case of buccal-lingual-masticatory syndrome with involuntary tongue protrusion reported to develop in a 77-year-old female after 5 weeks of fluoxetine therapy and which completely resolved over the next few months following drug discontinuation), <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonia</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="4142366" conceptname="Ten">epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>/<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, immune-related <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorders</span> developing in patients with risk factors including drugs associated with such reactions and worsening of pre-existing <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorders</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, QT prolongation, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span><span class="Sup">1</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (including Torsades de Pointes–type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>), <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, and <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behaviors</span><span class="Sup">1</span>.<br><br><span class="Sup">1</span>These terms represent serious adverse events, but do not meet the definition for adverse drug reactions. They are included here because of their seriousness.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<br><p class="First">As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc.) is a possibility.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Monoamine Oxidase Inhibitors (MAOI)</h2>
<p class="First"><span class="Italics">[see <a href="#Section_2.9">Dosage and Administration (2.9,</a><a href="#Section_2.10">2.10)</a>, <a href="#Section_4.2">Contraindications (4.1)</a>, and <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CNS Acting Drugs</h2>
<br><p class="First">Caution is advised if the concomitant administration of fluoxetine and such drugs is required. In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Serotonergic Drugs</h2>
<p class="First"><span class="Italics">[see <a href="#Section_2.9">Dosage and Administration (2.9,</a><a href="#Section_2.10">2.10)</a>, <a href="#Section_4.2">Contraindications (4.1)</a>, and <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, Warfarin)</h2>
<br><p class="First">Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Altered anticoagulant effects, including increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, have been reported when SNRIs or SSRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when fluoxetine is initiated or discontinued <span class="Italics">[see <a href="#Section_5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Electroconvulsive Therapy (ECT)</h2>
<br><p class="First">There are no clinical studies establishing the benefit of the combined use of ECT and fluoxetine. There have been rare reports of prolonged <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients on fluoxetine receiving ECT treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Potential for Other Drugs to affect Fluoxetine</h2>
<br><p class="First"><span class="Italics">Drugs Tightly Bound to Plasma Proteins —</span> Because fluoxetine is tightly bound to plasma proteins, adverse effects may result from displacement of protein-bound fluoxetine by other tightly-bound drugs <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Potential for Fluoxetine to affect Other Drugs</h2>
<br><p class="First"><span class="Italics">Pimozide </span><span class="Italics">— </span>Concomitant use in patients taking pimozide is contraindicated. Pimozide can prolong the QT interval. Fluoxetine can increase the level of pimozide through inhibition of CYP2D6. Fluoxetine can also prolong the QT interval. Clinical studies of pimozide with other antidepressants demonstrate an increase in drug interaction or QT prolongation. While a specific study with pimozide and fluoxetine has not been conducted, the potential for drug interactions or QT prolongation warrants restricting the concurrent use of pimozide and fluoxetine <span class="Italics">[see <a href="#Section_4.1">Contraindications (4.2)</a>, <a href="#Section_5.10">Warnings and Precautions (5.11)</a>, and <a href="#Section_7.8">Drug Interactions (7.8)</a>]</span>.<span class="Italics"><br><br>Thioridazine — </span>Thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued, because of the risk of QT Prolongation <span class="Italics">[see <a href="#Section_4.1">Contraindications (4.2)</a>, <a href="#Section_5.10">Warnings and Precautions (5.11)</a>, and <a href="#Section_7.8">Drug Interactions (7.8)</a>]</span>.<br><br>In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher C<span class="Sub">max</span> and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared with the rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity. Thus, this study suggests that drugs which inhibit CYP2D6, such as certain SSRIs, including fluoxetine, will produce elevated plasma levels of thioridazine.<br><br>Thioridazine administration produces a dose-related prolongation of the QT interval, which is associated with serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. This risk is expected to increase with fluoxetine-induced inhibition of thioridazine metabolism.<span class="Italics"></span><span class="Italics"><br><br>Drugs Metabolized by CYP2D6 —</span> Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index (see list below) should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs). Due to the risk of serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> potentially associated with elevated plasma levels of thioridazine, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued <span class="Italics">[see <a href="#Section_4.1">Contraindications (4.2</a>)]</span>. <span class="Italics"><br></span><span class="Italics"><br>Tricyclic Antidepressants (TCAs) </span><span class="Italics">— </span>In 2 studies, previously stable plasma levels of imipramine and desipramine have increased greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued <span class="Italics"><span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a> and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.<br><br>Benzodiazepines </span><span class="Italics">— </span>The half-life of concurrently administered diazepam may be prolonged in some patients <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>. Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels.<span class="Italics"><br></span><span class="Italics"><br>Antipsychotics —</span> Some clinical data suggests a possible pharmacodynamic and/or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine. <span class="Italics"><br><br>Anticonvulsants —</span> Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">anticonvulsant toxicity</span> following initiation of concomitant fluoxetine treatment.<span class="Italics"><br><br></span><span class="Italics">Lithium — </span>There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> and increased serotonergic effects have been reported. Lithium levels should be monitored when these drugs are administered concomitantly<span class="Italics"><span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span></span><span class="Italics">.</span><span class="Italics"><br><br>Drugs Tightly Bound to Plasma Proteins </span><span class="Italics">— </span>Because fluoxetine is tightly bound to plasma proteins, the administration of fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.<span class="Italics"><br><br>Drugs Metabolized by CYP3A4 </span><span class="Italics">— </span>In an <span class="Italics">in vivo</span> interaction study involving coadministration of fluoxetine with single doses of terfenadine (a CYP3A4 substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine.<br><br>Additionally, <span class="Italics">in vitro</span> studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam. These data indicate that fluoxetine’s extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.<span class="Italics"><br><br>Olanzapine</span><span class="Italics"> — </span>Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended.<span class="Italics"><br><br>When using fluoxetine and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for </span><span class="Italics">Symbyax.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Drugs that Prolong the QT Interval</h2>
<p class="First">Do not use fluoxetine in combination with thioridazine or pimozide. Use fluoxetine with caution in combination with other drugs that cause QT prolongation. These include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Fluoxetine is primarily metabolized by CYP2D6. Concomitant treatment with CYP2D6 inhibitors can increase the concentration of fluoxetine. Concomitant use of other highly protein-bound drugs can increase the concentration of fluoxetine <span class="Italics">[see <a href="#Section_4.1">Contraindications (4.2)</a>, <a href="#Section_5.10">Warnings and Precautions (5.11)</a>, <a href="#Section_7.7">Drug Interactions (7.7)</a>, and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<br><p class="First"><span class="Italics">When using fluoxetine and olanzapine in combination, also refer to the Use in Specific Populations section of the package </span><span class="Italics">insert for Symbyax.</span></p>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">
                              Pregnancy Category C</span> — Fluoxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure.<br><br><span class="Italics">Treatment of Pregnant Women during the First Trimester </span>— There are no adequate and well-controlled clinical studies on the use of fluoxetine in pregnant women. Results of a number of published epidemiological studies assessing the risk of fluoxetine exposure during the first trimester of pregnancy have demonstrated inconsistent results. More than 10 cohort studies and case-control studies failed to demonstrate an increased risk for congenital malformations overall. However, one prospective cohort study conducted by the European Network of Teratology Information Services reported an increased risk of cardiovascular malformations in infants born to women (N = 253) exposed to fluoxetine during the first trimester of pregnancy compared to infants of women (N = 1,359) who were not exposed to fluoxetine. There was no specific pattern of cardiovascular malformations. Overall, however, a causal relationship has not been established.<br><br><span class="Italics">Nonteratogenic Effects</span> — Neonates exposed to fluoxetine and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].<br><br></span>Infants exposed to SSRIs in pregnancy may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). PPHN occurs in 1 to 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiological studies suggest a positive statistical association between SSRI use (including fluoxetine) in pregnancy and PPHN. Other studies do not show a significant statistical association.<br><br>Physicians should also note the results of a prospective longitudinal study of 201 pregnant women with a history of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission. Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> compared to those women who remained on antidepressant medication throughout pregnancy.<br><br>When treating a pregnant woman with fluoxetine, the physician should carefully consider both the potential risks of taking an SSRI, along with the established benefits of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with an antidepressant. The decision can only be made on a case by case basis <span class="Italics">[see <a href="#Section_2.7">Dosage and Administration (2.7)</a>]</span>.<br><br><span class="Italics">Animal Data</span> — In embryo-fetal development studies in rats and rabbits, there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> following administration of fluoxetine at doses up to 12.5 and 15 mg/kg/day, respectively (1.5 and 3.6 times, respectively, the maximum recommended human dose (MRHD) of 80 mg on a mg/m<span class="Sup">2</span> basis) throughout organogenesis. However, in rat reproduction studies, an increase in stillborn pups, a decrease in pup weight, and an increase in pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> during the first 7 days postpartum occurred following maternal exposure to 12 mg/kg/day (1.5 times the MRHD on a mg/m<span class="Sup">2</span> basis) during gestation or 7.5 mg/kg/day (0.9 times the MRHD on a mg/m<span class="Sup">2</span> basis) during gestation and lactation. There was no evidence of developmental <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> in the surviving offspring of rats treated with 12 mg/kg/day during gestation. The no-effect dose for rat pup mortality was 5 mg/kg/day (0.6 times the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<br><p class="First">The effect of fluoxetine on labor and delivery in humans is unknown. However, because fluoxetine crosses the placenta and because of the possibility that fluoxetine may have adverse effects on the newborn, fluoxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<br><p class="First">Because fluoxetine is excreted in human milk, nursing while on fluoxetine is not recommended. In one breast-milk sample, the concentration of fluoxetine plus norfluoxetine was 70.4 ng/mL. The concentration in the mother’s plasma was 295.0 ng/mL. No adverse effects on the infant were reported. In another case, an infant nursed by a mother on fluoxetine developed <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and watery stools. The infant’s plasma drug levels were 340 ng/mL of fluoxetine and 208 ng/mL of norfluoxetine on the second day of feeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<br><p class="First"><span class="Italics">Use of fluoxetin</span><span class="Italics">e in children -</span> The efficacy of fluoxetine for the treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> was demonstrated in two 8- to 9-week placebo-controlled clinical trials with 315 pediatric outpatients ages 8 to ≤18 <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>.<br><br>The efficacy of fluoxetine for the treatment of OCD was demonstrated in one 13-week placebo-controlled clinical trial with 103 pediatric outpatients ages 7 to &lt;18 <span class="Italics">[see <a href="#Section_14.2">Clinical Studies (14.2)</a></span><span class="Italics">]</span>.<br><br>The safety and effectiveness in pediatric patients &lt;8 years of age in Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> and &lt;7 years of age in OCD have not been established.<br><br>Fluoxetine pharmacokinetics were evaluated in 21 pediatric patients (ages 6 to ≤18) with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> or OCD <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.<br><br>The acute adverse reaction profiles observed in the 3 studies (N=418 randomized; 228 fluoxetine-treated, 190 placebo-treated) were generally similar to that observed in adult studies with fluoxetine. The longer-term adverse reaction profile observed in the 19-week Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> study (N=219 randomized; 109 fluoxetine-treated, 110 placebo-treated) was also similar to that observed in adult trials with fluoxetine <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a>]</span>.<br><br><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic reaction</span>, including <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, was reported in 6 (1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, 5 <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>) out of 228 (2.6%) fluoxetine-treated patients and in 0 out of 190 (0%) placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> led to the discontinuation of 4 (1.8%) fluoxetine-treated patients from the acute phases of the 3 studies combined. Consequently, regular monitoring for the occurrence of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> is recommended.<br><br>As with other SSRIs, decreased <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> has been observed in association with the use of fluoxetine in children and adolescent patients. After 19 weeks of treatment in a clinical trial, pediatric subjects treated with fluoxetine gained an average of 1.1 cm less in height and 1.1 kg less in weight than subjects treated with placebo. In addition, fluoxetine treatment was associated with a decrease in alkaline phosphatase levels. The safety of fluoxetine treatment for pediatric patients has not been systematically assessed for chronic treatment longer than several months in duration. In particular, there are no studies that directly evaluate the longer-term effects of fluoxetine on the growth, development and maturation of children and adolescent patients. Therefore, height and weight should be monitored periodically in pediatric patients receiving fluoxetine <span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>]</span>.<br><br>Fluoxetine is approved for use in pediatric patients with MDD and OCD <span class="Italics">[see <a href="#Section_0">Box Warning</a> and <a href="#Section_5.1">Warnings and Precautions (5.1</a>)</span><span class="Italics">]</span>. Anyone considering the use of fluoxetine in a child or adolescent must balance the potential risks with the clinical need.<br><br><span class="Italics">Animal Data</span> - Significant toxicity on muscle tissue, neurobehavior, reproductive organs, and bone development has been observed following exposure of juvenile rats to fluoxetine from weaning through maturity. Oral administration of fluoxetine to rats from weaning postnatal day 21 through adulthood day 90 at 3, 10, or 30 mg/kg/day was associated with testicular degeneration and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, epididymal vacuolation and hypospermia (at 30 mg/kg/day corresponding to plasma exposures [AUC] approximately 5 to 10 times the average AUC in pediatric patients at the MRHD of 20 mg/day), increased serum levels of creatine kinase (at AUC as low as 1 to 2 times the average AUC in pediatric patients at the MRHD of 20 mg/day), skeletal <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle degeneration</span> and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, decreased femur length/growth and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (at AUC 5 to 10 times the average AUC in pediatric patients at the MRHD of 20 mg/day). The high dose of 30 mg/kg/day exceeded a maximum tolerated dose. When animals were evaluated after a drug-free period (up to 11 weeks after cessation of dosing), fluoxetine was associated with neurobehavioral abnormalities (decreased reactivity at AUC as low as approximately 0.1 to 0.2 times the average AUC in pediatric patients at the MRHD and learning deficit at the high dose), and reproductive functional impairment (decreased mating at all doses and impaired fertility at the high dose). In addition, the testicular and epididymal microscopic lesions and decreased sperm concentrations found in high dose group were also observed, indicating that the drug effects on reproductive organs are irreversible. The reversibility of fluoxetine-induced <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> was not assessed.<br><br>These fluoxetine toxicities in juvenile rats have not been observed in adult animals. Plasma exposures (AUC) to fluoxetine in juvenile rats receiving 3, 10, or 30 mg/kg/day doses in this study are approximately 0.1 to 0.2, 1 to 2, and 5 to 10 times, respectively, the average exposure in pediatric patients receiving the MRHD of 20 mg/day. Rat exposures to the major metabolite, norfluoxetine, are approximately 0.3 to 0.8, 1 to 8, and 3 to 20 times, respectively, the pediatric exposure at the MRHD.<br><br>A specific effect on bone development was reported in juvenile mice administered fluoxetine by the intraperitoneal route to 4 week old mice for 4 weeks at doses 0.5 and 2 times the oral MRHD of 20 mg/day on mg/m<span class="Sup">2</span> basis. There was a decrease in bone mineralization and density at both doses, but the overall growth (body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or femur length) was not affected.<br><br>Safety and effectiveness of fluoxetine and olanzapine in combination in patients less than 10 years of age have not been established.<br><span class="Italics"><br>Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<br><p class="First">US fluoxetine clinical trials included 687 patients ≥65 years of age and 93 patients ≥75 years of age. The efficacy in geriatric patients has been established <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>. For pharmacokinetic information in geriatric patients, <span class="Italics">[see <a href="#Section_12.4">Clinical Pharmacology (12.4)</a>]</span>. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. SNRIs and SSRIs, including fluoxetine, have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse reaction <span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.9)</a>]</span>.<br><br>Clinical studies of olanzapine and fluoxetine in combination did not include sufficient numbers of patients ≥65 years of age to determine whether they respond differently from younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<br><p class="First">In subjects with cirrhosis of the liver, the clearances of fluoxetine and its active metabolite, norfluoxetine, were decreased, thus increasing the elimination half-lives of these substances. A lower or less frequent dose of fluoxetine should be used in patients with cirrhosis. Caution is advised when using fluoxetine in patients with diseases or conditions that could affect its metabolism <span class="Italics">[see </span><span class="Italics"><a href="#Section_2.7">Dosage and Administration (2.7</a>) and <a href="#Section_12.4">Clinical Pharmacology (12.4)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34087-7">
<a name="Section_9.3"></a><a name="section-9.1"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<br><p class="First">Fluoxetine has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. While the premarketing clinical experience with fluoxetine did not reveal any tendency for a withdrawal syndrome or any <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug seeking behavior</span>, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of fluoxetine (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.1"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<br><p class="First">Worldwide exposure to fluoxetine hydrochloride is estimated to be over 38 million patients (circa 1999). Of the 1578 cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involving fluoxetine hydrochloride, alone or with other drugs, reported from this population, there were 195 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>.<br><br>Among 633 adult patients who overdosed on fluoxetine hydrochloride alone, 34 resulted in a fatal outcome, 378 completely recovered, and 15 patients experienced sequelae after overdosage, including abnormal accommodation, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, unresponsiveness, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, pulmonary dysfunction, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, elevated blood pressure, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>. The remaining 206 patients had an unknown outcome. The most common signs and symptoms associated with non-fatal overdosage were <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The largest known ingestion of fluoxetine hydrochloride in adult patients was 8 grams in a patient who took fluoxetine alone and who subsequently recovered. However, in an adult patient who took fluoxetine alone, an ingestion as low as 520 mg has been associated with lethal outcome, but causality has not been established.<br><br>Among pediatric patients (ages 3 months to 17 years), there were 156 cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involving fluoxetine alone or in combination with other drugs. Six patients died, 127 patients completely recovered, 1 patient experienced <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and 22 patients had an unknown outcome. One of the six fatalities was a 9-year-old boy who had a history of OCD, Tourette’s syndrome with <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span>, <span class="product-label-link" type="condition" conceptid="4149353" conceptname="Attention deficit hyperactivity disorder, predominantly inattentive type">attention deficit disorder</span>, and fetal alcohol syndrome. He had been receiving 100 mg of fluoxetine daily for 6 months in addition to clonidine, methylphenidate, and promethazine. Mixed-drug ingestion or other methods of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> complicated all 6 <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in children that resulted in fatalities. The largest ingestion in pediatric patients was 3 grams which was nonlethal.<br><br>Other important adverse reactions reported with fluoxetine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (single or multiple drugs) include <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, ECG abnormalities (such as nodal rhythm, QT interval prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>-like reactions, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.2"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Animal Experience</h2>
<br><p class="First">Studies in animals do not provide precise or necessarily valid information about the treatment of human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. However, animal experiments can provide useful insights into possible treatment strategies.<br><br>The oral median lethal dose in rats and mice was found to be 452 and 248 mg/kg, respectively. Acute high oral doses produced hyperirritability and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in several animal species.<br><br>Among 6 dogs purposely overdosed with oral fluoxetine, 5 experienced <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizures</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> stopped immediately upon the bolus intravenous administration of a standard veterinary dose of diazepam. In this short-term study, the lowest plasma concentration at which a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> occurred was only twice the maximum plasma concentration seen in humans taking 80 mg/day, chronically.<br><br>In a separate single-dose study, the ECG of dogs given high doses did not reveal prolongation of the PR, QRS, or QT intervals. <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and an increase in blood pressure were observed. Consequently, the value of the ECG in predicting cardiac toxicity is unknown. Nonetheless, the ECG should ordinarily be monitored in cases of human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> <span class="Italics">[see <a href="#Section_10.3">Overdosage (10.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.3"></a><a name="section-10.3"></a><p></p>
<h2>10.3 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">For current information on the management of fluoxetine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, contact a certified poison control center (1-800-222-1222 or www.poison.org). Treatment should consist of those general measures employed in the management of overdosage with any drug. Consider the possibility of multi-drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.<br><br>Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. Use general supportive and symptomatic measures. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended.<br><br>Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for fluoxetine are known.<br><br>A specific caution involves patients who are taking or have recently taken fluoxetine and might ingest excessive quantities of a TCA. In such a case, accumulation of the parent tricyclic and/or an active metabolite may increase the possibility of clinically significant sequelae and extend the time needed for close medical observation <span class="Italics">[see <a href="#Section_7.7">Drug Interactions (7.7)</a>]</span>.<br><br>For specific information about overdosage with olanzapine and fluoxetine in combination, refer to the Overdosage section of the Symbyax package insert.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<br><p class="First">Fluoxetine capsules, USP are a selective serotonin reuptake inhibitor for oral administration. It is also marketed for the treatment of <span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">premenstrual dysphoric disorder</span> (Sarafem<span class="Sup">®</span>, fluoxetine hydrochloride). It is designated (±)-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-<span class="Italics">p</span>-tolyl)oxy]propylamine hydrochloride and has the empirical formula of C<span class="Sub">17</span>H<span class="Sub">18</span>F<span class="Sub">3</span>NO•HCl. Its molecular weight is 345.79. The structural formula is: </p>
<br><div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23899405-007b-48d9-82a9-a530b8e90784&amp;name=Fluoxetine7.jpg"></div>
<br><p>Fluoxetine hydrochloride, USP is a white to off-white crystalline powder with a solubility of 14 mg/mL in water.<br><br>Each capsule contains fluoxetine hydrochloride equivalent to 10 mg (32.3 μmol), 20 mg (64.7 μmol), or 40 mg (129.3 μmol) of fluoxetine. The capsules also contain the following inactive ingredients: pregelatinized starch (maize [corn]), colloidal silicon dioxide, gelatin, sodium lauryl sulphate, FD&amp;C Blue #1, FD&amp;C Red #3, and titanium dioxide. In addition 20 mg capsules also contains D&amp;C Yellow #10 and 10 mg capsules also contains FD&amp;C Yellow #6. The capsules are printed with edible ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac and strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<br><p class="First">Although the exact mechanism of fluoxetine is unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<br><p class="First">Studies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets. Studies in animals also suggest that fluoxetine is a much more potent uptake inhibitor of serotonin than of norepinephrine.<br><br>Antagonism of muscarinic, histaminergic, and α<span class="Sub">1</span>-adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently <span class="Italics">in vitro</span> than do the tricyclic drugs.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<br><p class="First"><span class="Italics">Systemic Bioavailability </span>— In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.<br><br>Food does not appear to affect the systemic bioavailability of fluoxetine, although it may delay its absorption by 1 to 2 hours, which is probably not clinically significant. Thus, fluoxetine may be administered with or without food.<span class="Italics"><br><br>Protein Binding </span>— Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound <span class="Italics">in vitro</span> to human serum proteins, including albumin and α<span class="Sub">1</span>-glycoprotein. The interaction between fluoxetine and other highly protein-bound drugs has not been fully evaluated, but may be important. <span class="Italics"><br><br>Enantiomers </span>— Fluoxetine is a racemic mixture (50/50) of <span class="Italics">R</span>-fluoxetine and <span class="Italics">S</span>-fluoxetine enantiomers. In animal models, both enantiomers are specific and potent serotonin uptake inhibitors with essentially equivalent pharmacologic activity. The <span class="Italics">S</span>-fluoxetine enantiomer is eliminated more slowly and is the predominant enantiomer present in plasma at steady state.<span class="Italics"><br><br>Metabolism </span>— Fluoxetine is extensively metabolized in the liver to norfluoxetine and a number of other unidentified metabolites. The only identified active metabolite, norfluoxetine, is formed by demethylation of fluoxetine. In animal models, <span class="Italics">S</span>-norfluoxetine is a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to <span class="Italics">R</span>- or <span class="Italics">S</span>-fluoxetine. <span class="Italics">R</span>-norfluoxetine is significantly less potent than the parent drug in the inhibition of serotonin uptake. The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney.<span class="Italics"><br><br>Variability in Metabolism </span>— A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as “poor metabolizers? of drugs such as debrisoquin, dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized <span class="Italics">S</span>-fluoxetine at a slower rate and thus achieved higher concentrations of <span class="Italics">S</span>-fluoxetine. Consequently, concentrations of <span class="Italics">S</span>-norfluoxetine at steady state were lower. The metabolism of <span class="Italics">R</span>-fluoxetine in these poor metabolizers appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 active enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative, nonsaturable pathways (non-2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steady-state concentration rather than increasing without limit.<br><br>Because fluoxetine’s metabolism, like that of a number of other compounds including TCAs and other selective serotonin reuptake inhibitors (SSRIs), involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system (such as the TCAs) may lead to drug interactions <span class="Italics">[see <a href="#Section_7.7">Drug Interactions (7.7)</a>]</span>.<span class="Italics"><br><br>Accumulation and Slow Elimination </span>— The relatively slow elimination of fluoxetine (elimination half-life of 1 to 3 days after acute administration and 4 to 6 days after chronic administration) and its active metabolite, norfluoxetine (elimination half-life of 4 to 16 days after acute and chronic administration), leads to significant accumulation of these active species in chronic use and delayed attainment of steady state, even when a fixed dose is used <span class="Italics">[see <a href="#Section_5.13">Warnings and Precautions (5.14)</a>]</span>. After 30 days of dosing at 40 mg/day, plasma concentrations of fluoxetine in the range of 91 to 302 ng/mL and norfluoxetine in the range of 72 to 258 ng/mL have been observed. Plasma concentrations of fluoxetine were higher than those predicted by single-dose studies, because fluoxetine’s metabolism is not proportional to dose. Norfluoxetine, however, appears to have linear pharmacokinetics. Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days. Steady-state levels after prolonged dosing are similar to levels seen at 4 to 5 weeks.<br><br>The long elimination half-lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug substance will persist in the body for weeks (primarily depending on individual patient characteristics, previous dosing regimen, and length of previous therapy at discontinuation). This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of fluoxetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-12.4"></a><p></p>
<h2>12.4 Specific Populations</h2>
<br><p class="First"><span class="Italics">Liver Disease </span>— As might be predicted from its primary site of metabolism, liver impairment can affect the elimination of fluoxetine. The elimination half-life of fluoxetine was prolonged in a study of cirrhotic patients, with a mean of 7.6 days compared with the range of 2 to 3 days seen in subjects without liver disease; norfluoxetine elimination was also delayed, with a mean duration of 12 days for cirrhotic patients compared with the range of 7 to 9 days in normal subjects. This suggests that the use of fluoxetine in patients with liver disease must be approached with caution. If fluoxetine is administered to patients with liver disease, a lower or less frequent dose should be used <span class="Italics">[see <a href="#Section_2.7">Dosage and Administration (2.7</a>), <a href="#Section_8.6">Use in Specific Populations (8.6)</a>]</span>.<span class="Italics"><br><br><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> </span>— In depressed patients on dialysis (N=12), fluoxetine administered as 20 mg once daily for 2 months produced steady-state fluoxetine and norfluoxetine plasma concentrations comparable with those seen in patients with normal renal function. While the possibility exists that renally excreted metabolites of fluoxetine may accumulate to higher levels in patients with severe renal dysfunction, use of a lower or less frequent dose is not routinely necessary in renally impaired patients.<span class="Italics"><br><br>Geriatric Pharmacokinetics </span>— The disposition of single doses of fluoxetine in healthy elderly subjects (&gt;65 years of age) did not differ significantly from that in younger normal subjects. However, given the long half-life and nonlinear disposition of the drug, a single-dose study is not adequate to rule out the possibility of altered pharmacokinetics in the elderly, particularly if they have systemic illness or are receiving multiple drugs for concomitant diseases. The effects of age upon the metabolism of fluoxetine have been investigated in 260 elderly but otherwise healthy depressed patients (≥60 years of age) who received 20 mg fluoxetine for 6 weeks. Combined fluoxetine plus norfluoxetine plasma concentrations were 209.3 ± 85.7 ng/mL at the end of 6 weeks. No unusual age-associated pattern of adverse reactions was observed in those elderly patients.<span class="Italics"><br><br>Pediatric Pharmacokinetics (children and adolescents) </span>— Fluoxetine pharmacokinetics were evaluated in 21 pediatric patients (10 children ages 6 to &lt;13, 11 adolescents ages 13 to &lt;18) diagnosed with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> or <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD). Fluoxetine 20 mg/day was administered for up to 62 days. The average steady-state concentrations of fluoxetine in these children were 2-fold higher than in adolescents (171 and 86 ng/mL, respectively). The average norfluoxetine steady-state concentrations in these children were 1.5-fold higher than in adolescents (195 and 113 ng/mL, respectively). These differences can be almost entirely explained by differences in weight. No gender-associated difference in fluoxetine pharmacokinetics was observed. Similar ranges of fluoxetine and norfluoxetine plasma concentrations were observed in another study in 94 pediatric patients (ages 8 to &lt;18) diagnosed with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>.<br><br>Higher average steady-state fluoxetine and norfluoxetine concentrations were observed in children relative to adults; however, these concentrations were within the range of concentrations observed in the adult population. As in adults, fluoxetine and norfluoxetine accumulated extensively following multiple oral dosing; steady-state concentrations were achieved within 3 to 4 weeks of daily dosing. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<br><p class="First"><span class="Italics">Carcinogenicity </span>— The dietary administration of fluoxetine to rats and mice for 2 years at doses of up to 10 and 12 mg/kg/day, respectively [approximately 1.2 and 0.7 times, respectively, the maximum recommended human dose (MRHD) of 80 mg on a mg/m<span class="Sup">2</span> basis], produced no evidence of carcinogenicity.<span class="Italics"><br><br>Mutagenicity </span>— Fluoxetine and norfluoxetine have been shown to have no genotoxic effects based on the following assays: bacterial mutation assay, DNA repair assay in cultured rat hepatocytes, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and <span class="Italics">in vivo</span> sister chromatid exchange assay in Chinese hamster bone marrow cells.<br><span class="Italics"><br>Impairment of Fertility </span>— Two fertility studies conducted in adult rats at doses of up to 7.5 and 12.5 mg/kg/day (approximately 0.9 and 1.5 times the MRHD on a mg/m<span class="Sup">2</span> basis) indicated that fluoxetine had no adverse effects on fertility. However, adverse effects on fertility were seen when juvenile rats were treated with fluoxetine <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<br><p class="First">Phospholipids are increased in some tissues of mice, rats, and dogs given fluoxetine chronically. This effect is reversible after cessation of fluoxetine treatment. Phospholipid accumulation in animals has been observed with many cationic amphiphilic drugs, including fenfluramine, imipramine, and ranitidine. The significance of this effect in humans is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Efficacy for fluoxetine was established for the:</p>
<br><ul class="Disc">
<li>Acute and maintenance treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> in adults, and children and adolescents (8 to 18 years) in 7 short-term and 2 long-term, placebo-controlled trials <span class="Italics">[see <a href="#Section_14.1">Clinical Studies 14.1</a>]</span>.</li>
<li>Acute treatment of obsessions and compulsions in adults, and children and adolescents (7 to 17 years) with <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD) in 3 short-term placebo-controlled trials <span class="Italics">[see <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.</li>
<li>Acute and maintenance treatment of binge-eating and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> behaviors in adult patients with moderate to severe <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span> in 3 short-term and 1 long-term, placebo-controlled trials <span class="Italics">[see <a href="#Section_14.3">Clinical Studies (14.3)</a>]</span>.</li>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span>, with or without <span class="product-label-link" type="condition" conceptid="4321835" conceptname="Agoraphobia">agoraphobia</span>, in adult patients in 2 short-term, placebo-controlled trials <span class="Italics">[see <a href="#Section_14.4">Clinical Studies (14.4)</a>]</span>.</li>
</ul>
<p>Efficacy for fluoxetine and olanzapine in combination was established for the:</p>
<br><ul class="Disc"><li>Acute treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> in <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> in adults.</li></ul>
<br><p><span class="Italics">Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<p><span class="Italics"><br>When using </span><span class="Italics">fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<br><p class="First"><span class="Italics">Daily Dosing<br><br>Adult — </span>The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span><span class="Italics">. </span>Fluoxetine was shown to be significantly more effective than placebo as measured by the Hamilton <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (HAM-D). Fluoxetine was also significantly more effective than placebo on the HAM-D subscores for <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>, and the <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> subfactor.<br><br>Two 6-week controlled studies (N=671, randomized) comparing fluoxetine 20 mg and placebo have shown fluoxetine 20 mg daily to be effective in the treatment of elderly patients (≥60 years of age) with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>. In these studies, fluoxetine produced a significantly higher rate of response and remission as defined, respectively, by a 50% decrease in the HAM-D score and a total endpoint HAM-D score of ≤8. Fluoxetine was well tolerated and the rate of treatment discontinuations due to adverse reactions did not differ between fluoxetine (12%) and placebo (9%).<br><br>A study was conducted involving depressed outpatients who had responded (modified HAMD-17 score of ≤7 during each of the last 3 weeks of open-label treatment and absence of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> by DSM-III-R criteria) by the end of an initial 12-week open-treatment phase on fluoxetine 20 mg/day. These patients (N=298) were randomized to continuation on double-blind fluoxetine 20 mg/day or placebo. At 38 weeks (50 weeks total), a statistically significantly lower relapse rate (defined as symptoms sufficient to meet a diagnosis of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> for 2 weeks or a modified HAMD-17 score of ≥14 for 3 weeks) was observed for patients taking fluoxetine compared with those on placebo.<span class="Italics"><br><br>Pediatric (children and adolescents) </span><span class="Italics">— </span>The efficacy of fluoxetine 20 mg/day in children and adolescents (N=315 randomized; 170 children ages 8 to &lt;13, 145 adolescents ages 13 to ≤18) was studied in two 8- to 9-week placebo-controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>.<br><br>In both studies independently, fluoxetine produced a statistically significantly greater mean change on the Childhood <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale-Revised (CDRS-R) total score from baseline to endpoint than did placebo.<br><br>Subgroup analyses on the CDRS-R total score did not suggest any differential responsiveness on the basis of age or gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-14.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span></h2>
<br><p class="First"><span class="Italics">Adult </span>— The effectiveness of fluoxetine for the treatment of <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD) was demonstrated in two 13-week, multicenter, parallel group studies (Studies 1 and 2) of adult outpatients who received fixed fluoxetine doses of 20, 40, or 60 mg/day (on a once-a-day schedule, in the morning) or placebo. Patients in both studies had moderate to severe OCD (DSM-III-R), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS, total score) ranging from 22 to 26. In Study 1, patients receiving fluoxetine experienced mean reductions of approximately 4 to 6 units on the YBOCS total score, compared with a 1-unit reduction for placebo patients. In Study 2, patients receiving fluoxetine experienced mean reductions of approximately 4 to 9 units on the YBOCS total score, compared with a 1-unit reduction for placebo patients. While there was no indication of a dose-response relationship for effectiveness in Study 1, a dose-response relationship was observed in Study 2, with numerically better responses in the 2 higher dose groups. The following table provides the outcome classification by treatment group on the Clinical Global Impression (CGI) improvement scale for Studies 1 and 2 combined:</p>
<br><a name="i359d5127-cfa5-4d64-8a17-a27410854d37"></a><table width="70%">
<caption><span>Table 6</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="5">Outcome Classification (%) on CGI Improvement Scale for<br>Completers in Pool of Two OCD Studies</th></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left" colspan="2"></th>
<th class="Rrule" align="center" colspan="3">Fluoxetine</th>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Outcome Classification</td>
<td class="Rrule" align="center">Placebo</td>
<td class="Rrule" align="center">20 mg</td>
<td class="Rrule" align="center">40 mg</td>
<td class="Rrule" align="center">60 mg</td>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Worse</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">No change</td>
<td class="Rrule" align="center">64%</td>
<td class="Rrule" align="center">41%</td>
<td class="Rrule" align="center">33%</td>
<td class="Rrule" align="center">29%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Minimally improved</td>
<td class="Rrule" align="center">17%</td>
<td class="Rrule" align="center">23%</td>
<td class="Rrule" align="center">28%</td>
<td class="Rrule" align="center">24%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Much improved</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">28%</td>
<td class="Rrule" align="center">27%</td>
<td class="Rrule" align="center">28%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Very much improved</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">19%</td>
</tr>
</tbody>
</table>
<br><p>Exploratory analyses for age and gender effects on outcome did not suggest any differential responsiveness on the basis of age or sex.<span class="Italics"><br><br>Pediatric (children and adolescents) </span>— In one 13-week clinical trial in pediatric patients (N=103 randomized; 75 children ages 7 to &lt;13, 28 adolescents ages 13 to &lt;18) with OCD (DSM-IV), patients received fluoxetine 10 mg/day for 2 weeks, followed by 20 mg/day for 2 weeks. The dose was then adjusted in the range of 20 to 60 mg/day on the basis of clinical response and tolerability. Fluoxetine produced a statistically significantly greater mean change from baseline to endpoint than did placebo as measured by the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS).<br><br>Subgroup analyses on outcome did not suggest any differential responsiveness on the basis of age or gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-14.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span></h2>
<br><p class="First">The effectiveness of fluoxetine for the treatment of <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span> was demonstrated in two 8-week and one 16-week, multicenter, parallel group studies of adult outpatients meeting DSM-III-R criteria for <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span>. Patients in the 8-week studies received either 20 or 60 mg/day of fluoxetine or placebo in the morning. Patients in the 16-week study received a fixed fluoxetine dose of 60 mg/day (once a day) or placebo. Patients in these 3 studies had moderate to severe <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia</span> with median binge-eating and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> frequencies ranging from 7 to 10 per week and 5 to 9 per week, respectively. In these 3 studies, fluoxetine 60 mg, but not 20 mg, was statistically significantly superior to placebo in reducing the number of binge-eating and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> episodes per week. The statistically significantly superior effect of 60 mg versus placebo was present as early as Week 1 and persisted throughout each study. The fluoxetine-related reduction in bulimic episodes appeared to be independent of baseline <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> as assessed by the Hamilton <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale. In each of these 3 studies, the treatment effect, as measured by differences between fluoxetine 60 mg and placebo on median reduction from baseline in frequency of bulimic behaviors at endpoint, ranged from 1 to 2 episodes per week for binge-eating and 2 to 4 episodes per week for <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The size of the effect was related to baseline frequency, with greater reductions seen in patients with higher baseline frequencies. Although some patients achieved freedom from binge-eating and purging as a result of treatment, for the majority, the benefit was a partial reduction in the frequency of binge-eating and purging.<br><br>In a longer-term trial, 150 patients meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span>, purging subtype, who had responded during a single-blind, 8-week acute treatment phase with fluoxetine 60 mg/day, were randomized to continuation of fluoxetine 60 mg/day or placebo, for up to 52 weeks of observation for relapse. Response during the single-blind phase was defined by having achieved at least a 50% decrease in <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> frequency compared with baseline. Relapse during the double-blind phase was defined as a persistent return to baseline <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> frequency or physician judgment that the patient had relapsed. Patients receiving continued fluoxetine 60 mg/day experienced a significantly longer time to relapse over the subsequent 52 weeks compared with those receiving placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.4"></a><a name="section-14.4"></a><p></p>
<h2>14.4 <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span></h2>
<br><p class="First">The effectiveness of fluoxetine in the treatment of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of <span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span> (DSM-IV), with or without <span class="product-label-link" type="condition" conceptid="4321835" conceptname="Agoraphobia">agoraphobia</span>.<br><br>Study 1 (N=180 randomized) was a 12-week flexible-dose study. Fluoxetine was initiated at 10 mg/day for the first week, after which patients were dosed in the range of 20 to 60 mg/day on the basis of clinical response and tolerability. A statistically significantly greater percentage of fluoxetine-treated patients were free from <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> at endpoint than placebo-treated patients, 42% versus 28%, respectively.<br><br>Study 2 (N=214 randomized) was a 12-week flexible-dose study. Fluoxetine was initiated at 10 mg/day for the first week, after which patients were dosed in a range of 20 to 60 mg/day on the basis of clinical response and tolerability. A statistically significantly greater percentage of fluoxetine-treated patients were free from <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> at endpoint than placebo-treated patients, 62% versus 44%, respectively. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16.1"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<br><p class="First">Fluoxetine Capsules, USP 10 mg** are white to off white powder filled in size “4? hard gelatin capsules with opaque light blue colored cap and opaque light orange colored body imprinted “SG? on cap and “113? on body with black ink.</p>
<br><p>                         Bottles of 30                     NDC 50228-113-30</p>
<p>                         Bottles of 1000                 NDC 50228-113-10</p>
<br><p>Fluoxetine Capsules USP, 20 mg** are white to off white powder filled in size “2? hard gelatin capsules with opaque light blue colored cap and opaque light green colored body imprinted “SG? on cap and “114? on body with black ink.</p>
<br><p>                         Bottles of 30                    NDC 50228-114-30</p>
<p>                         Bottles of 1000                NDC 50228-114-10</p>
<br><p>Fluoxetine Capsules USP, 40 mg** are white to off white powder filled in size “0? hard gelatin capsules with opaque light blue colored cap and opaque white colored body imprinted “SG? on cap and “115? on body with black ink.</p>
<br><p>                         Bottles of 30                  NDC 50228-115-30</p>
<p>                         Bottles of 500                NDC 50228-115-05</p>
<p><br>**Fluoxetine base equivalent.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="Section_16.2"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<br><p class="First"> Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) <span class="Italics">[see USP Controlled Room Temperature].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<br><p class="First"><span class="Italics">See the <a href="#Section_19">FDA-approved Medication Guide</a>.</span><br><br>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking fluoxetine as monotherapy or in combination with olanzapine. When using fluoxetine and olanzapine in combination, also refer to the Patient Counseling Information section of the package insert for Symbyax.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1 General Information</h2>
<br><p class="First">Healthcare providers should instruct their patients to read the Medication Guide before starting therapy with fluoxetine and to reread it each time the prescription is renewed.<br><br>Healthcare providers should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with fluoxetine and should counsel them in its appropriate use. Healthcare providers should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.<br><br>Patients should be advised of the following issues and asked to alert their healthcare provider if these occur while taking fluoxetine.<br><span class="Italics"><br>When using fluoxetine and olanzapine in combination, also refer to the Medication Guide for Symbyax.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults</h2>
<br><p class="First">Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication <span class="Italics">[see <a href="#Section_0">Box Warning</a> and <a href="#Section_5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First"><br>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the concomitant use of fluoxetine and other serotonergic agents including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John’s Wort <span class="Italics">[see <a href="#Section_4.2">Contraindications (4.1)</a>, <a href="#Section_5.2">Warnings and Precautions (5.2)</a>, and <a href="#Section_7.3">Drug Interactions (7.3)</a>]</span>.<br><br>Patients should be advised of the signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> that may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular changes (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be cautioned to seek medical care immediately if they experience these symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-16.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<br><p class="First">Patients should be advised to notify their physician if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>]. </span>Patients should also be advised of the signs and symptoms associated with a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, eyes, or mouth, or have trouble breathing. Patients should be cautioned to seek medical care immediately if they experience these symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<br><p class="First">Patients should be cautioned about the concomitant use of fluoxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents have been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.7)</a> and <a href="#Section_7.4">Drug Interactions (7.4)</a>]. </span>Patients should be advised to call their doctor if they experience any increased or unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> while taking fluoxetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.12"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">Patients should be advised that taking fluoxetine can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Pre-existing <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is almost always open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> because angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, when diagnosed, can be treated definitively with iridectomy. Open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is not a risk factor for angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> procedure (e.g., iridectomy), if they are susceptible. <span class="Italics">[See <a href="#Section_5.17">Warnings and Precautions (5.8)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.6"></a><a name="section-16.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<br><p class="First">Patients should be advised that <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> has been reported as a result of treatment with SNRIs and SSRIs, including fluoxetine. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. More severe and/or acute cases have been associated with <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.11"></a><a name="section-16.8"></a><p></p>
<h2>17.8 QT Prolongation</h2>
<p class="First">Patients should be advised that QT interval prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> have been reported in patients treated with fluoxetine. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> include fast, slow, or irregular heart rate, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, which may indicate serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> <span class="Italics">[see <a href="#Section_5.10">Warnings and Precautions (5.11)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.7"></a><a name="section-16.9"></a><p></p>
<h2>17.9 Potential for Cognitive and Motor Impairment</h2>
<br><p class="First">Fluoxetine may impair judgment, thinking, or motor skills. Patients should be advised to avoid driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected <span class="Italics">[see <a href="#Section_5.12">Warnings and Precautions (5.13)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.8"></a><a name="section-16.10"></a><p></p>
<h2>17.10 Use of Concomitant Medications</h2>
<br><p class="First">Patients should be advised to inform their physician if they are taking, or plan to take, any prescription medication, including Symbyax, Sarafem, or over-the-counter drugs, including herbal supplements or alcohol. Patients should also be advised to inform their physicians if they plan to discontinue any medications they are taking while on fluoxetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.9"></a><a name="section-16.11"></a><p></p>
<h2>17.11 Discontinuation of Treatment</h2>
<br><p class="First">Patients should be advised to take fluoxetine exactly as prescribed, and to continue taking fluoxetine as prescribed even after their symptoms improve. Patients should be advised that they should not alter their dosing regimen, or stop taking fluoxetine without consulting their physician <span class="Italics">[see <a href="#Section_5.14">Warnings and Precautions (5.15)</a>]</span>. Patients should be advised to consult with their healthcare provider if their symptoms do not improve with fluoxetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.10"></a><a name="section-16.12"></a><p></p>
<h2>17.12 Use in Specific Populations</h2>
<br><p class="First"><span class="Italics">Pregnancy </span>— Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Fluoxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus <span class="Italics">[see <a href="#Section_8.1">Use in Specific Populations (8.1)</a></span><span class="Italics">]</span>.<br><span class="Italics"><br>Nursing Mothers</span> — Patients should be advised to notify their physician if they intend to breast-feed an infant during therapy. Because fluoxetine is excreted in human milk, nursing while taking fluoxetine is not recommended <span class="Italics">[see <a href="#Section_8.3">Use in Specific Populations (8.3)</a>]</span>.<br><span class="Italics"><br>Pediatric Use of fluoxetine</span> — Fluoxetine is approved for use in pediatric patients with MDD and OCD <span class="Italics">[see <a href="#Section_0">Box Warning</a> and <a href="#Section_5.1">Warnings  and Precautions (5.1)</a></span><span class="Italics">]</span>. Limited evidence is available concerning the longer-term effects of fluoxetine on the development and maturation of children and adolescent patients. Height and weight should be monitored periodically in pediatric patients receiving fluoxetine. <span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a> and <a href="#Section_8.4">Use in Specific Populations (8.4)</a>]</span>.<br><br><span class="Italics">Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.<br></span><br>Symbyax<span class="Sup">®</span> and Sarafem<span class="Sup">®</span> are registered trademarks of Eli Lilly.<br><br>Manufactured by:<br>
                           ScieGen Pharmaceuticals Inc<br>
                           Hauppauge, NY 11788<br>USA<br><br>Rev. 02/15
						   <br><br>Barcode.</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<h1>                                                                                                                                            Medication Guide</h1>
<p class="First">
                                                                                                                                                           Fluoxetine Capsules, USP
                        <br>                                                                                                                                               (floo-ox-e-teen) 
                      <br><br>Read the Medication Guide that comes with fluoxetine capsules before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about.<br><br><span class="Bold">What is the most important information I should know about fluoxetine capsules?</span><br><br>Fluoxetine capsules and other antidepressant medicines may cause serious side effects, including: <br><br><span class="Bold">1. Suicidal thoughts or actions:</span></p>
<br><ul class="Disc">
<li>
<span class="Bold">Fluoxetine capsules </span><span class="Bold">and other antidepressant medicines may increase suicidal thoughts or actions</span> in some children, teenagers, or young adults within the <span class="Bold">first few months of treatment or when the dose is changed. </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> or other serious mental illnesses are the most important causes of suicidal thoughts or actions. </li>
<li>Watch for these changes and call your healthcare provider right away if you notice: <ul class="Disc">
<li>New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe. </li>
<li>Pay particular attention to such changes when fluoxetine capsules is started or when the dose is changed. </li>
</ul>
</li>
</ul>
<br><p>Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms. <br><br><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you: </span></p>
<br><ul class="Disc">
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>acting on dangerous impulses</li>
<li>acting aggressive or violent</li>
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>, angry or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span></li>
<li>trouble sleeping</li>
<li>an increase in activity or talking more than what is normal for you</li>
<li>other unusual changes in behavior or mood </li>
</ul>
<br><p><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency. Fluoxetine capsules </span><span class="Bold">may be associated with these serious side effects:</span><br><br><span class="Bold">2.  <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>. This condition can be life-threatening and may include:</span></p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or other changes in mental status</li>
<li>coordination problems or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> (overactive reflexes)</li>
<li>racing heartbeat, high or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></li>
<li>seizures </li>
</ul>
<br><p><span class="Bold">3.</span><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>: </span></p>
<br><ul class="Disc">
<li>trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, tongue, eyes or mouth</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">welts</span> (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>) or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, alone or with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
</ul>
<br><p><span class="Bold">4. </span><span class="Bold">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: </span>Fluoxetine capsules and other antidepressant medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, especially if you take the blood thinner warfarin (Coumadin<span class="Sup">®</span>, Jantoven<span class="Sup">®</span>), a non-steroidal anti-inflammatory drug (NSAIDs, like ibuprofen or naproxen), or aspirin.<br><br><span class="Bold">5. Visual problems:</span></p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span></li>
<li>changes in vision</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in or around the eye</li>
</ul>
<p>Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.</p>
<br><br><p><span class="Bold">6. </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></span></p>
<br><span class="Bold"></span><p><span class="Bold">7. </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic episodes</span>:</span></p>
<br><ul class="Disc">
<li>greatly increased energy</li>
<li>severe trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="4115026" conceptname="Racing thoughts">racing thoughts</span></li>
<li>reckless behavior</li>
<li>unusually grand ideas</li>
<li>excessive happiness or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>talking more or faster than usual</li>
</ul>
<br><p><span class="Bold">8. Changes in appetite or weight.</span> Children and adolescents should have height and weight monitored during treatment.<br><br><span class="Bold">9. Low salt (sodium) levels in the blood.</span> Elderly people may be at greater risk for this. Symptoms may include: </p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or feeling unsteady</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems concentrating or thinking or memory problems </li>
</ul>
<br><p><span class="Bold"><br>10.  Changes in the electrical activity of your heart (QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>). This condition can be life threatening. The symptoms may include:</span></p>
<br><ul class="Disc">
<li>fast, slow, or irregular heartbeat </li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
</ul>
<br><p><span class="Bold">Do not stop fluoxetine capsules </span><span class="Bold">without first talking to your healthcare provider.</span> Stopping fluoxetine capsules too quickly may cause serious symptoms including:</p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, high or low mood, feeling <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> or changes in sleep habits</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="439396" conceptname="Injury due to electrical exposure">electric shock</span>-like sensations, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
</ul>
<br><p><span class="Bold">What are fluoxetine capsules?</span><br><br>Fluoxetine capsules are a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It is important to talk with your healthcare provider about the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider. <br><br>Fluoxetine capsules are used to treat:</p>
<br><ul class="Disc">
<li>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD)</li>
<li><span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD)</li>
<li><span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">Bulimia Nervosa</span>*</li>
<li><span class="product-label-link" type="condition" conceptid="436074" conceptname="Panic disorder">Panic Disorder</span>*</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>, taken with olanzapine (Zyprexa)*</li>
</ul>
<br><p>*Not approved for use in children<br><span class="Italics"><br>Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.<br></span><br>Talk to your healthcare provider if you do not think that your condition is getting better with fluoxetine capsules treatment. <br><br><span class="Bold">Who should not take fluoxetine capsules?<br><br></span>Do not take fluoxetine capsules if you:</p>
<br><ul class="Disc">
<li>are allergic to fluoxetine hydrochloride or any of the ingredients in fluoxetine capsules. See the end of this Medication Guide for a complete list of ingredients in fluoxetine capsules.</li>
<li>take a Monoamine Oxidase Inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid.<ul class="Disc">
<li>Do not take an MAOI within 5 weeks of stopping fluoxetine capsules unless directed to do so by your physician.</li>
<li>Do not start fluoxetine capsules if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your physician.</li>
</ul>
</li>
</ul>
<br><p><span class="Bold">People who take fluoxetine capsules close in time to an MAOI may have serious or even life-threatening side effects. Get medical help right away if you have any of these symptoms:<br><br><br></span></p>
<ul class="Disc">
<li>high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>uncontrolled <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span></li>
<li>stiff muscles</li>
<li>rapid changes in heart rate or blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (pass out) </li>
</ul>
<br><ul class="Disc">
<li><span class="Bold">take Mellaril<span class="Sup">® </span>(thioridazine). Do not take Mellaril<span class="Sup">® </span>within 5 weeks of stopping fluoxetine capsules because this can cause serious heart rhythm problems or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>.</span></li>
<li><span class="Bold">take the antipsychotic medicine pimozide (Orap<span class="Sup">®</span>) because this can cause serious heart problems. </span></li>
</ul>
<br><p><span class="Bold">What should I tell my healthcare provider before taking fluoxetine capsules? Ask if you are not sure.</span><br><br>Before starting fluoxetine capsules, tell your healthcare provider if you:</p>
<br><ul class="Disc">
<li>Are taking certain drugs or treatments such as:<ul class="Disc">
<li>Triptans used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span></li>
<li>Medicines used to treat mood, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or thought disorders, including tricyclics, lithium, buspirone, SSRIs, SNRIs, MAOIs or antipsychotics </li>
<li>Tramadol and fentanyl</li>
<li>Over-the-counter supplements such as tryptophan or St. John’s Wort </li>
</ul>
</li>
<li>Electroconvulsive therapy (ECT)</li>
<li>have liver problems</li>
<li>have kidney problems</li>
<li>have heart problems</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></li>
<li>have bipolar disorder or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span></li>
<li>have low sodium levels in your blood</li>
<li>have a history of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>have high blood pressure</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>are pregnant or plan to become pregnant. It is not known if fluoxetine capsules will harm your unborn baby. Talk to your healthcare provider about the benefits and risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> during pregnancy.</li>
<li>are breast-feeding or plan to breast-feed. Some fluoxetine capsules may pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking fluoxetine capsules.</li>
</ul>
<br><p><span class="Bold">Tell your healthcare provider about all the medicines that you take, </span>including prescription and non-prescription medicines, vitamins, and herbal supplements. Fluoxetine capsules and some medicines may interact with each other, may not work as well, or may cause serious side effects. <br><br>Your healthcare provider or pharmacist can tell you if it is safe to take fluoxetine capsules with your other medicines. Do not start or stop any medicine while taking fluoxetine capsules without talking to your healthcare provider first.<br><br>If you take fluoxetine capsules, you should not take any other medicines that contain fluoxetine hydrochloride including:</p>
<br><div class="Warning">
<a name="Section_19.1"></a><a name="section-17.1"></a><p></p>
<br><ul class="Disc">
<li>Symbyax </li>
<li>Sarafem </li>
<li>Prozac Weekly </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_19.2"></a><a name="section-17.1"></a><p></p>
<p class="First"><span class="Bold">How should I take fluoxetine capsules?</span><br></p>
<ul class="Disc">
<li>Take fluoxetine capsules exactly as prescribed. Your healthcare provider may need to change the dose of fluoxetine capsules until it is the right dose for you. </li>
<li>Fluoxetine capsules may be taken with or without food. </li>
<li>If you miss a dose of fluoxetine capsules, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of fluoxetine capsules at the same time. </li>
<li>If you take too much fluoxetine capsules, call your healthcare provider or poison control center right away, or get emergency treatment. </li>
</ul>
<br><p><span class="Bold">What should I avoid while taking fluoxetine capsules?</span><br><br>Fluoxetine capsules can cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how fluoxetine capsules affects you. Do not drink alcohol while using fluoxetine capsules. <br><br><span class="Bold">What are the possible side effects of fluoxetine capsules?<br><br></span>Fluoxetine capsules may cause serious side effects, including:<br></p>
<ul class="Disc">
<li>See <span class="Bold">“What is the most important information I should know about fluoxetine capsules??</span>
</li>
<li>
<span class="Bold">Problems with blood sugar control. </span>People who have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and take fluoxetine capsules may have problems with low blood sugar while taking fluoxetine capsules. High blood sugar can happen when fluoxetine capsules is stopped. Your healthcare provider may need to change the dose of your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines when you start or stop taking fluoxetine capsules. </li>
<li><span class="Bold">Feeling anxious or trouble sleeping </span></li>
</ul>
<br><p>Common possible side effects in people who take fluoxetine capsules include: </p>
<br><ul class="Disc">
<li>unusual dreams </li>
<li>sexual problems </li>
<li>loss of appetite, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu symptoms</span> </li>
<li>feeling tired or fatigued </li>
<li>change in sleep habits </li>
<li><span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span> or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> </li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> </li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> </li>
<li>feeling anxious or nervous </li>
<li><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> </li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
</ul>
<br><p>Other side effects in children and adolescents include:</p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span> </li>
<li>abnormal increase in muscle movement or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> </li>
<li><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleed</span> </li>
<li>urinating more often </li>
<li>heavy menstrual periods </li>
<li>possible slowed growth rate and weight change. Your child’s height and weight should be monitored during treatment with fluoxetine capsules. </li>
</ul>
<br><p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of fluoxetine capsules. For more information, ask your healthcare provider or pharmacist.<br><br><span class="Bold">CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088. </span><br><br><span class="Bold">How should I store fluoxetine capsules?</span></p>
<br><ul class="Disc">
<li>Store fluoxetine capsules at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). <span class="Italics"> [see USP Controlled Room Temperature]. </span>
</li>
<li>Keep fluoxetine capsules away from light. </li>
<li>Keep fluoxetine capsules bottle closed tightly.</li>
</ul>
<br><p><span class="Bold">Keep fluoxetine capsules and all medicines out of the reach of children.</span><br><br><span class="Bold">General information about fluoxetine capsules</span><br><br>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use fluoxetine capsules for a condition for which it was not prescribed. Do not give fluoxetine capsules to other people, even if they have the same condition. It may harm them.<br><br>This Medication Guide summarizes the most important information about fluoxetine capsules. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about fluoxetine capsules that is written for healthcare professionals.<br><br>For more information about fluoxetine capsules call ScieGen Pharmaceuticals Inc at 1-855-724-3436.<br><br><span class="Bold">What are the ingredients in fluoxetine </span><span class="Bold">capsules? </span><br><br>Active ingredient: fluoxetine hydrochloride, USP <br><br>Inactive ingredients: pregelatinized starch (maize [corn]), colloidal silicon dioxide, gelatin, sodium lauryl sulphate, FD&amp;C Blue #1, FD&amp;C Red #3, and titanium dioxide. In addition 20 mg capsules also contains D&amp;C Yellow #10 and 10 mg capsules also contains FD&amp;C Yellow #6. The capsules are printed with edible ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac and strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution.<br><br><span><a name="OLE_LINK3"></a>Symbyax<span class="Sup">® </span>and Sarafem<span class="Sup">®</span> are registered trademarks of Eli Lilly and Company. </span><br>Mellaril<span class="Sup">®</span> is a registered trademark of Novartis AG Corporation. <br>Orap<span class="Sup">®</span> is a registered trademark of Teva Pharmaceuticals USA. <br>Coumadin<span class="Sup">®</span> is a registered trademark of Bristol Myers Squibb. <br>Jantoven<span class="Sup">®</span> is a registered trademark of Upsher-Smith Laboratories Inc. <br>Zyprexa<span class="Sup">®</span> is a registered trademark of Eli Lilly and Company. <br><br><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span><br><br>Rev. 02/15<br><br>Manufactured by:<br>
                           ScieGen Pharmaceuticals Inc
                           <br>Hauppauge, NY 11788<br> USA </p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-18"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 50228-113-30</span></p>
<p><span class="Bold"> Fluoxetine Capsules, USP<br>10 mg </span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">30 Capsules</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense the accompanying Medication Guide to each patient.
                  </p>
<div class="Figure"><img alt="10 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23899405-007b-48d9-82a9-a530b8e90784&amp;name=Fluoxetine1.jpg"></div>
<p><span class="Bold">NDC 50228-113-10</span></p>
<p><span class="Bold"> Fluoxetine Capsules, USP<br>10 mg </span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">1000 Capsules</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense the accompanying Medication Guide to each patient.
                  </p>
<div class="Figure"><img alt="10 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23899405-007b-48d9-82a9-a530b8e90784&amp;name=Fluoxetine2.jpg"></div>
<p><span class="Bold">NDC 50228-114-30</span></p>
<p><span class="Bold"> Fluoxetine Capsules, USP<br>20 mg </span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">30 Capsules</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense the accompanying Medication Guide to each patient.
                  </p>
<div class="Figure"><img alt="20 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23899405-007b-48d9-82a9-a530b8e90784&amp;name=Fluoxetine3.jpg"></div>
<p><span class="Bold">NDC 50228-114-10</span></p>
<p><span class="Bold"> Fluoxetine Capsules, USP<br>20 mg </span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">1000 Capsules</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense the accompanying Medication Guide to each patient.
                  </p>
<div class="Figure"><img alt="20 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23899405-007b-48d9-82a9-a530b8e90784&amp;name=Fluoxetine4.jpg"></div>
<p><span class="Bold">NDC 50228-115-30</span></p>
<p><span class="Bold"> Fluoxetine Capsules, USP<br>40 mg </span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">30 Capsules</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense the accompanying Medication Guide to each patient.
                  </p>
<div class="Figure"><img alt="40 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23899405-007b-48d9-82a9-a530b8e90784&amp;name=Fluoxetine5.jpg"></div>
<p><span class="Bold">NDC 50228-115-05</span></p>
<p><span class="Bold"> Fluoxetine Capsules, USP<br>40 mg </span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">500 Capsules</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense the accompanying Medication Guide to each patient.
                  </p>
<div class="Figure"><img alt="40 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=23899405-007b-48d9-82a9-a530b8e90784&amp;name=Fluoxetine6.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUOXETINE 		
					</strong><br><span class="contentTableReg">fluoxetine hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50228-113</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, PREGELATINIZED CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Opaque Light Blue) , ORANGE (Opaque Light Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SG;113</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50228-113-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50228-113-10</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA204597</td>
<td class="formItem">03/16/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUOXETINE 		
					</strong><br><span class="contentTableReg">fluoxetine hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50228-114</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, PREGELATINIZED CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Opaque Light Blue) , GREEN (Opaque Light Green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SG;114</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50228-114-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50228-114-10</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA204597</td>
<td class="formItem">03/16/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUOXETINE 		
					</strong><br><span class="contentTableReg">fluoxetine hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50228-115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, PREGELATINIZED CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Opaque Light Blue) , WHITE (Opaque White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SG;115</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50228-115-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50228-115-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA204597</td>
<td class="formItem">03/16/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ScieGen Pharmaceuticals, Inc.
							(832859669)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ScieGen Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">832859669</td>
<td class="formItem">MANUFACTURE(50228-113, 50228-114, 50228-115), ANALYSIS(50228-113, 50228-114, 50228-115)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e4cde93f-709e-487a-a6ab-5327ca055eda</div>
<div>Set id: 23899405-007b-48d9-82a9-a530b8e90784</div>
<div>Version: 1</div>
<div>Effective Time: 20150216</div>
</div>
</div> <div class="DistributorName">ScieGen Pharmaceuticals, Inc.</div></p>
</body></html>
